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Abstract
ELECTROSPRAY IONIZATION MASS SPECTROMETRY FOR THE
CHARACTERIZATION OF COVALENT AND NONCOVALENT POLYNUCLEAR
PLATINUM COMPOUNDS INTERACTING WITH BIO-MOLECULES

By
John B. Mangrum, Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2010
Director: Dr. Nicholas P. Farrell
Professor
Department of Chemistry

Polynuclear platinum compounds represent a new class of potential platinum anticancer
therapeutics. Derived from the most widely used platinum anticancer drug, cisplatin, these novel
compounds are distinct in their interactions with bio-molecules. The effectiveness of platinum
anticancer agents is influenced by three pharmacological factors: (i) their resistance to
deactivating sulfur nucleophiles, (ii) the ability to gain cellular entry and efficient cellular
uptake, and (iii) the ability to form stable and specific complexes with DNA. BBR 3464, the
first multinuclear platinum compound to reach phase II clinical trials, has created a new
approach to cancer drug design. Large, highly charged platinum compounds have been shown to

xvi
form favorable covalent and noncovalent interactions with bio-molecular structures. Compounds
such as BBR 3464, form an immediate pre-association with anionic structures on biomolecules
before covalent attachment. To better characterize these interactions, a new set of compounds
was designed that exclusively interacts via electrostatic associations and hydrogen bonding.
The investigation of noncovalent complexes between DNA, proteins, and peptides with a variety
of synthetic and biological relevant structures has become increasingly more common with the
coupling of electrospray ionization and mass spectrometry (ESI-MS). Mass spectrometry has
been useful to the drug design community by allowing the rapid and accurate characterization of
drug binding sites. In the first project we have explored the use of collision induced dissociation
(CID) to map the potential binding sites of noncovalent polynuclear platinum compounds of
varying size and charge with an antisense oligonucleotide of the Bcl-2 sequence. In the second
project, the gas-phase dissociation and stabilizing effects of these polynuclear platinum
compounds on duplex DNA were determined. Correlations between the size and charge of
associating platinum compounds were determined by comparing the change in gas phase stability
under CID conditions. Additionally, the association of these new types of noncovalently binding
polynuclear platinum compounds was investigated with model cell surface structures such as
anionic heparan sulfate and phospholipids.

1

Chapter 1:
Platinum and Cancer Biology Background

1.1. Emergence of Platinum as an Anticancer Agent
The anti-cancer therapeutic cisplatin or cis-[PtCl2(NH3)2], first synthesized in 1845, was
serendipitously shown to first inhibit the mitosis of bacteria in the lab and then shortly afterwards
found to possess anti-tumor activity in 1969.1 The development of cisplatin has been well
documented. Upon gaining clinical approval in 1978, it has shown remarkable utility in a variety
of human carcinomas, such as ovarian, breast, bladder, head, and neck.2 Testicular cancer cases
that once were fatal, have shown a >90% success rate in treatment.3 With the increasing
successes of cisplatin, many platinum based compounds were constructed and tested for
improvements of the anti-cancer effectiveness. In 2006, it was reported that over 3000 platinum
complexes had been tested for improvements and/or alternatives to cisplatin in the treatment of
cancer.4 However, only 28 (roughly 1%) have shown enough activity to warrant entry into
clinical trials.4 Currently only two other platinum based therapies have been approved for the
treatment of human cancers, carboplatin and oxaliplatin.5 See figure 1.1.

2
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Pt
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H3N
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Cisplatin

Carboplatin

Oxaliplatin

Figure 1.1. FDA approved platinum compounds for the treatment of cancer

1.2 Binding of Platinum Complexes to Biomolecules
The cytotoxicity of platinum drugs is primarily affected by three pharmacological factors: 1.)
cellular uptake and efflux, 2.) the frequency and resulting structure of target adducts (DNA), and
3.) the metabolic profile resulting from reactions with sulfur containing proteins and peptides.
Although cisplatin has been used with much success for more than 30 years, the exact
biochemical mechanism of action is still relatively ambiguous. A series of structure-activity
relationship rules that define the favorable characteristics a successful therapeutic should possess
was suggested by Cleare and Hoeschele in 19736-8. Those rules are broadly defined as: (a)
possess a zero net charge (b) contain two leaving groups or one bidentate leaving group (c)
have chloride leaving groups or similar liagands (d)

leaving groups oriented in the cis-

configuration (e) no hydroxy or hydroxo ligands as it increases toxicity and (f) have inert nonleaving groups such as amines.
Platinum compounds induce tumor damage by the stimulation of apoptosis. This process is
mediated by the activation of signal transduction pathways that lead to the death receptor

3
mechanisms.9 The currently accepted mode of action for cisplatin is that the compound induces
cytotoxicity via binding to nuclear DNA which may activate a variety of signalling pathways
such as p53, Bcl-2, caspases, and MAPK to name a few. Additionally, disruption of transcription
and replication mechanisms also exist.4
The anti-cancer properties of cisplatin results from the displacement of the two cis chloride
ligands and subsequent replacement with aquo ligands, which readily undergo substitution
resulting in platination of the biological targets. (See Figure 1.2)

+
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Cl
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Cl

H3N
H 3N

Pt

Pt

Cl
OH2

+
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H 3N
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Pt

OH2

Pt

Cl

Figure 1.2. Cisplatin binding scheme with duplex DNA
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Displacement of chloride ligands is hindered in physiological conditions due to the high
concentration of chloride in blood, approaching 100mM. This enables cisplatin to reach the outer
cellular surface still as a neutral molecule which helps promote cellular translocation. Once
inside the cell the chloride concentration drops to approximately 4-20mM, which is low enough
for the hydrolysis of cisplatin to occur.10-12

B-DNA

1,2 Intrastrand

1,2 Interstrand

cross-link

cross-link

Figure 1.3 DNA distortion upon cisplatin covalent modification2

The accepted mechanism by which cisplatin exerts its anti-cancer activity begins with a specific
DNA binding profile and follows with a cascade of cellular protein recognition interactions. As
seen in the binding scheme figure 1.3, cisplatin forms primarily bifunctional intrastrand adducts
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Figure 1.4. Structures of DNA nucleobases. The purine
N7 site is the preferential binding site of Pt based

between two adjacent guanine (G) nucleosides, and to a much lesser extent between guanine and
adenosine (GA) nucleosides.13 The end result is platinum bound to the electron dense N7 site of
the guanine nucleosides. A much less common binding profile between cisplatin and DNA
occurs with interstrand crosslinks with guanine and cytosine (C) and the formation of 1,3
intrastrand crosslinks between G-x-G nucleosides.13 The formation of the GG intrastrand
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crosslinks results in a large bending of the DNA, which subsequently can be recognized by High
Mobility Group Proteins (HMG) preventing the normal repair mechanisms from occurring. 14, 15
The 1,2-GG intrastrand binding causes the helix to bend toward the major groove (~ 40-80º) with
an unwinding of the helix of around 20-30º.2 This distortion which is recognized by the HMG
binding domain proteins prevents the DNA replication and transcription and ultimately leads
apoptosis.2
The extensive use of platinum drugs such as cisplatin, is limited due to intrinsic resistance by
certain human cancer cell lines or the acquired resistance following initial treatment.16 The
development of acquired resistance is believed to occur through one or more processes: reduced
uptake into cancer cells; increased tolerance to the DNA cisplatin interaction; more efficient
DNA repair; and cisplatin deactivation via elevated levels of glutathione.17, 18

Figure 1.5. The 1,2 Intrastrand and 1,2 Interstrand crosslinks formed
between DNA and Cisplatin

7
The use of cisplatin is also associated with dose-related side effects in addition to the intrinsic
and acquired resistance mentioned above.16,

19

The main dose limiting toxicity (DLT) of

cisplatin is nephrotoxicity at 60-120 mg/m2.4
In efforts to lower the side effects and increase the cytotoxicity in cisplatin resistant cancer cells,
newer variations of the platinum diamine [Pt(NH3)2]center have shown success. One such
compound that was designed to lower the side effects is carboplatin16, diammine[ 1,2cyclobutane-dicarboxyylato]platinum(II) (see figure 1).

Carboplatin has very little to no

associated nephrotoxicity and reduced oto-, neuro-, and gastrointestinal toxicities.19, 20 The DLT
for this compound at around 900 mg/m2 is myelosuppression, bone marrow toxicity.6 As such,
the FDA approved carboplatin in 1989 and is currently sold by Bristol Myers-Squibb for the
treatment of advanced ovarian carcinoma.6, 21 As seen in figure 1.1, carboplatin is structurally
different from cisplatin in the fact that the labile chloride ligands are replaced with the more
structurally stable chelate ring which also improves solubility. As such, the carboplatin should
possess a slower binding profile with proteins and other deactivating bio-molecules. The third
mono-platinum compound to be granted FDA approval was oxaliplatin or trans-Ldiaminocyclohexaneoxalatoplatinum (II).6,21. (see figure 1.1)

Oxaliplatin is thought to

circumvent some of the associated cisplatin resistance because the large hydrophobic DACH
ligand aids in inhibition of DNA transcription.6, 23-25 The maximum DLT for Oxaliplatin is 200
mg/m2 with a reported increase in neuropathy.4 Oxaliplatin is currently marketed by SanofiSynthelabo for the treatment of advanced colon carcinomas.6
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1.3 Polynuclear Platinum Complexes
In 1989, Farrell and coworkers reported a di-nuclear platinum compound comprised of two
cisplatin centers bridged with aliphatic diamines of varying length, n = 4,5, & 6.26 This new
class of “multi-nuclear” compounds increased DNA binding over that of cisplatin, as was
measured through the inhibition of Eco R1 endonuclease activity.26 These di-nuclear complexes
were expanded to include trans platinum centers with only one chloride leaving group and
varying charge from 1+ to 3+.6 Polynuclear platinum anticancer drugs appear to redefine the
structure-activity rules for platinum chemotherapy drugs that Cleare and Hoeschele (see section
1.1.2) determined for cisplatin.6
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Figure 1.6. Polynuclear platinum compounds where (Y) represents the charged
flexible central linker. Examples include: spermine, spermidine, or trans-platinum
diamine-dihexane
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The basic structure for the polynuclear complexes is seen in figure 1.6. This new motif contains
two or more platinum coordination spheres linked with a variety of flexible linkers. The addition
of a charged central platinum moiety increases the overall charge of the compound, but also adds
additional hydrogen bonding character. This has been shown to add potency over di-nuclear
complexes with di-amino hexane linkers.
By having two monofunctional platinum coordination spheres separated by a greater distance,
the compounds are still able to bind DNA in a bifunctional manner, but now possess the ability
to span several nucleobases, creating different DNA distortions as compared to mononuclear
compounds.
As seen in figure 1.7, the polynuclear platinum compound BBR 3464 is capable of forming 1,4
and 1,6 interstrand cross-links, even 1,5 intrastrand crosslinks. The polynuclear motif exhibits a
distinctive mode of action, which is different than that of the mononuclear platinum compounds.
This dissimilar binding action is believed to be responsible for the effectiveness of BBR 3464 in
cisplatin resistant cell lines.27

In fact, the DNA adducts formed by BBR 3464, are not

structurally recognized by antibodies commonly associated with cisplatin adducts or the high
mobility group proteins27-30 It has been reported that BBR 3464 binds to DNA with a frequency
of crosslink formation of approximately 20% of the time, which is roughly three times the
occurrence of the mononuclear cisplatin.27, 28 The frequency of interstrand adduct formation is
influenced by the geometry of the platinum centers as well as the hydrogen bonding capacity of
the central linker group.6 Increasing the hydrogen bonding character of the linker results in a
decrease in the percentage of interstrand crosslink formations.6

10

1,4-Interstrand

1 1,5-Intrastrand
5-

1,6-Interstrand

Figure 1.7. BBR 3464 crosslinks formed with DNA

The cationic nature of these polynuclear complexes gives rise to an electrostatic attraction to the
anionic phosphate backbone of DNA. In fact, a preassociation prior to the covalent modification
of DNA has been identified for BBR 346431, as well as other polynuclear compounds, such as a
dinuclear platinium species with a 4,4′ -dipyrazolymethane (dpzm) linker by Wheate and
Collins.32 For the BBR 3464, it was determined that the nature and structure of the 1,4 cross link
was possibly dictated by the initial preassociation of the central linker in or around the minor
groove.31
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1.4 NonCovalent Polynuclear Platinum Complexes
As was discovered for the covalent binding polynuclear complexes, the preassociation of the
central tetraamineplatinum moiety directed the orientation of the DNA interaction.31 In efforts to
determine the nature of these preassociation events, a series of polynuclear platinum complexes
were synthesized that have the trans labile chloro ligands substituted for an ammonia or a
primary amine ligand. See figure 1.8 This exchange results in polynuclear platinum compounds
that possesses a high charge (4+ to 8+) and interacts with biomolecules exclusively through
electrostatic and hydrogen bonding interactions.

It has been shown that the electrostatic

interaction of these compounds induce a conformation change in canonical DNA sequences in
the B→A and B→Z.33 Increased cellular uptake in A2780 human ovarian tumor cells has been
shown for AH 44 and AH 78.34 Results show that when compared with the 4+ BBR 3464, the
uptake is increased approximately double for the 6+ AH 44 and up to five times higher for the 8+
AH 78.34 The results indicate that there are two possible reasons for the increase: the increase in
overall charge 6+ to 8+ and/or the addition of the dangling hexamine. In addition to cellular
uptake, studies of these compounds on the cytotoxicity in a panel of ovarian carcinoma cell lines
reveal they are not as toxic as the covalent polynuclear compound, but demonstrate toxicity
comparable to cisplatin nonetheless.34
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One of the three pharmacological factors that determine therapeutic efficacy is how compounds
interact with DNA. These noncovalent compounds have recently been shown to present a new
distinct third mode of DNA binding in contrast to the two longstanding modes of DNA
interaction, intercalation and groove binding.35

Crystallographic datum of AH 78 with a double

stranded dodecamer (Dickerson-Drew) reveal an interaction that can neither be classified as
intercalation or groove binding; instead the three square planar tetra am(m)ine Pt(II) coordination
spheres form a bidentate “phosphate clamp” with the phosphate oxygen.35 The single phosphate
oxygen accepts two hydrogen bonds, one from each of the cis oriented am(m)ines.35 The
interaction appears to be represented by two distinct binding modes: backbone tracking which
follows along the backbone of one strand and groove spanning which crosses over the minor
groove interacting with both strands.35 (See figure 1.9)
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Figure 1.8. Crystal structures of AH 78 with Dickerson-Drew Dodecamer19

In the backbone tracking motif, AH 78 associates with four out of five consecutive phosphates
along the single stranded backbone of the helix, utilizing six hydrogen bonds to stabilize the
structure.35 The addition of the flexible linker between the platinum coordination spheres allows
the compound to form “phosphate clamps” with the am(m)ines of two platinum coordination
spheres and the phosphate oxygens across the minor groove.35 This binding motif stabilizes the
duplex with four hydrogen bonds.35 The binding to the oxygens appears to be selective for the
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Figure 1.9 Phosphate clamp binding motif compared to the
structurally analogous arginine fork19

phosphate oxygen and no strong apparent interactions with other oxygens along the strands.
This is the first such “phosphate clamp” style binding motif aside from the guanidinium salt
bridges found in peptide-biomolecule interactions via arginine residues. see Figure 1.10. The
basic Y-shaped planar fork formed by the guaninidium group of the arginine forms interactions
with a variety of biological systems such as the acidic carboxylates found in the side chains of
aspartic and glutamic acids and post-translational modifications such as phosphorylation and
sulfation.22 The interactions between the basic guaninidium group of the arginine and acidic
groups of neighboring biomolecules are important for processes such as the stabilization of
protein structure, membrane transport, and enzymatic catalysis.22, 36-38

15
Project Overview
The research discussed in this dissertation focuses on obtaining a better understanding of
the interactions of novel polynuclear platinum compounds with a variety of biomolecules that
represent viable model systems in which anticancer therapeutic compounds encounter. The use
of mass spectrometry to investigate these platinum anticancer compounds with DNA is
demonstrated in Chapters 3 and 4. The potential of cell surface heparan sulfate to act as a
transport vehicle for these compounds is explored via stability studies in Chapter 5. Additional
research carried out during my graduate education is described in the appendix.
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Chapter 2:
Methods to investigate noncovalent interactions between polynuclear
platinum compounds and biomolecules
2.1 Electrospray Ionization
Electrospray ionization mass spectrometry (ESI-MS) has become an essential tool in the
process of drug discovery, playing a key role in the development of new therapeutics.1 The
utility of ESI-MS toward studying noncovalent interaction between biomolecules was first
demonstrated in 1991 with the work of Ganem et al.2
Electrospray ionization (ESI) is characterized as a soft ionization technique that allows the gentle
introduction of labile, as well as large, nonvolatile molecules into the gas phase.3 Applying a
potential difference of several thousand volts (~1-4 kV) between the ESI needle and the capillary
inlet on the mass spectrometer, a spray of highly charged droplets is formed.3-5 The ionization
process produces single and multiple charged ions of either positive or negative nature from an
aqueous solution in relation to applied polarity.4, 5 The majority of the work presented in this
dissertation involves negative electrospray ionization and therefore this description will detail the
application of the negative ionization process.
Electrospray Ionization occurs as a potential drop or difference is created between the
source needle and the mass spectrometer inlet, Figure 2.1.3, 4, 6 The generation of the electric
field between the two electrodes (~2-3mm) results in the formation of an inverted conical spray,
termed the Taylor cone.7 The Taylor cone is comprised of micron sized droplets (~2-3 µm in
diameter) of similarly charged solvent and analyte moieties that are then introduced into the mass
spectrometer.3, 6, 8-11
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Within the Taylor cone, the solute molecules have an overall negative charge which is the result
of using slightly basic ESI solutions, which aid in the deprotonation of the analyte. As the
molecules of solvent/analyte pass through the heated mass spectrometer inlet, they desolvate,
resulting in the density of charges in the droplet to increase. Desolvation occurs until the
Rayleigh limit, at which time, the coulombic repulsions from the excess of negative charges
within the droplet are equal the overall surface tension resulting in a coulombic explosion due to
droplet instability, and thus produces subsequent smaller droplets.8, 12

Figure 2.1. Schematic representation of two generally accepted methods of the
electrospray ionization (ESI) process.

Production of electrospray droplets in the ESI process is not fully understood. However, two
models are widely accepted. Dole proposed the charged residue model (CRM)13, which involves
the cascade of coulombic eruptions which proceed until the droplets contain only one solute

23
molecule and a select number of charges. The excess solvent shell continues to vaporize leaving
the solute ion with single or multiple charges.8, 12, 13 The second model proposed by Iribarne and
Thompson is termed the ion evaporation model (IEM).8, 12, 14 This model also begins with the
production of multiple droplets through the coulombic explosions, however the IEM process
continues only until the radii of the droplets become small enough so that the overall charge
density located on the surface of the droplet is high enough that the solute molecules inside the
droplet are deprotonated/protonated by the presence of hydroxyl/protons on the surface.3,
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Molecules of varying degrees of deprotonation/protonation can be brought into the gas-phase by
the presence of the strong electrostatic potential on the surface of the droplets as a way to remove
the excess of charge surrounding the droplet.8, 13

ESI is not tolerant of high salt or detergents in the spray solution. Therefore, for all the
experiments in this dissertation, an in-line microdialysis chamber was constructed to decrease the
presence of any interfering salts. The dialysis chamber has been described at length by Hannis et
al.15 Briefly, a 13,000 molecular weight cut off (MWCO) hollow regenerated cellulose fiber,
SpectroPor was installed between two 190 µm OD x 80 µm ID fused silica tubing, Polymicro.
The dialysis fiber is placed in a 20 mM ammonium acetate filled chamber. The sample of
interest is dissolved in 10 mM ammonium acetate and injected via syringe at 3 µL/min and
recollected.

Using this type of set up, approximately 99% desalting efficiency has been

achieved.15

The NH4+ displaces the Na+ or K+ adducts bound to the anionic sites of the

biomolecules and during the desolvation phase in electrospray the NH4+ leaves as NH3. Depicted
in figure 2.2 are ESI-MS spectra of a 13-mer oligonucleotide acquired directly from a vial and
the same oligonucleotide acquired after dialysis through the chamber.
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Figure 2.2. Micro-dialysis chamber illustrating pre and post dialysis spectra

2.2 Quadrupole Time of Flight Mass Spectrometry (QTOF-MS)
The experiments for this research were conducted on a QTOF-2 Waters/Micromass (Milford,
MA) equipped with a modified micro-electrospray ionization source. Time of flight instruments,
such as the one schematically illustrated in figure 2.3, can be thought of as a triple quadrupole
with the last quadrupole replaced with an orthogonal reflecting time of flight mass analyzer.16
The particular instrument from Waters/Micromass utilizes a hexapole (r.f. only hexapole ion
guide)/quadrupole/hexapole arrangement.
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Figure 2.3. Waters Qtof-2 Quadrupole-Time of Flight Instrument

Time of flight instruments operate on the principle that ions of different mass-to-charge (m/z)
have characteristically different velocities. The potential energy of the ion is converted to kinetic
energy upon acceleration. The relationship of m/z to velocity is as follows:

zeE = 1 / 2mv 2

(eqn. 2.1)
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where the kinetic energy of an ion ( ½ mv 2) is equal to the potential energy (zeE) where an
accelerating electric field (E) is available between the accelerator plates. The velocity of that ion
is therefore:
1/ 2

⎛ 2 zeE ⎞
v= ⎜
⎟
⎝ m ⎠

or v =

2 zeE
m

(eqn. 2.2)

Any two ions of the same charge, but different masses, will have different velocities under the
same experimental conditions.

Since it is impractical to measure the velocity of an ion, we consider the time = t, it takes for an
ion to travel a fixed distance = Leff.

t=

L eff
2 eU acc

m/z

(eqn. 2.3)

Ions with a smaller m/z reach the detector before those of a higher m/z value, as the higher m/z
ions have a much lower velocity and therefore a longer time spent in the flight tube.

t = C (m / z )

(eqn. 2.4)

Quadrupole times of flight instruments with orthogonally positioned reflectrons are able to
acquire fairly high resolution data, ~ 10,000 at full width half-maximum (FWHM). The
instrument resolution is given by equation 2.5 where m = detected peak mass and ∆m is the
FWHM of the detected peak.

R FWHM =

m
∆m

(eqn. 2.5)

27
In full scan mode, the ions generated through the ESI process are focused through the MS1
region with the RF hexapole lens and hexapole operating in the RF only mode.

The RF field

results in radial confinement of the ions by creating a potential well between the rods.16 In
addition, the higher pressures inside the MS1 region allow for radial and axial dampening, often
referred to as collisional cooling of the ions,17 thus reducing the energy spread and the overall
diameter of the ion packet.16
In the MS/MS mode, the quadrupole in MS1 is operated as a mass filter in order to transmit only
the parent ions of interest. By applying both the DC and RF voltages to the quadrupole rods, only
ions that have stable trajectories at the applied amplitudes of voltages will traverse down the
center, while ions of unstable trajectories will be neutralized by coming into contact with the
quadruple rods.17 The stability of ions exposed to RF-DC voltages is governed by the Mathieu
equation and visually represented by the Mathieu stability diagram. Upon acceleration of the ion
into the hexapole collision cell, it undergoes collision induced dissociation (CID) with neutral
argon gas resulting in fragment ions and depending on the applied collision energy possibly
remaining parent ions. The maximum amount of translational energy that can be converted to
the internal energy is given in equation 2.6.

E COM = E LAB [m c / (m c + m i )]

(eqn. 2.6)

The kinetic energy (ELAB) of the ion is provided by the applied electric fields in the instrument;
(mi) is the mass of the ion, and (mc) the mass of the collision gas atom.
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Looking at the equation, it is observable how collisions with larger neutral gas ions result in
more kinetic energy being converted into internal energy. For our particular instrument set up,
argon was chosen as the collision gas over nitrogen. Another factor influencing the CID of ions
is the overall charge state of the ion. The efficiency of CID scales in relation to its charge state
since the ion possesses a higher kinetic energy due to the effects of the electric fields of the
instrument. Therefore an identical molecule of two different charge states, (1+ and 3+) for
example, will have very different kinetic energies before CID. The 3+ ion will have three times
the kinetic energy and is therefore more likely to dissociate.
At each successful collision of the argon gas with the parent ion, some of the translational energy
is converted to internal energy and upon reaching an internal threshold specific to the isolated
ion, the ion will fragment. Leaving the collision cell, ions are accelerated into the MS2 region
and focused before encountering a pulsed electric field (usually several kHz in frequency)
supplied by the pusher plate in the orthogonal direction in relation to the their initial trajectory.
Following a final applied acceleration, the ions enter the field-free flight tube where they
encounter a series of grid plates or an electrostatic mirror termed the reflectron (figure 2.4).
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Figure 2.4. Schematic of a V-shaped reflectron depicting ions of differing kinetic
energy, but the same m/z values being corrected for increased resolution.17

The reflectron results in an increase in instrument resolution as it adjusts the velocities of ions
with similar m/z values. Ions of similar mass that might be separated in space due to differences
in kinetic energy enter the reflectron at different times. The reflectron electrostatic grid plates
apply a decelerating potential to the ions. So ions of higher kinetic energy (faster ions) enter the
reflectron and penetrate deeper into the grid plates than the lower kinetic energy (slower ions).
The same electric field that decelerated the ions coming in, now accelerates the ions out of the
reflectron back to their original velocity. Since the ions with lower kinetic energy penetrate less,
they leave the reflectron first followed by the higher kinetic ions which penetrated deeper into
the reflectron, thus increasing its path length. However, despite the fact that the ions of lower
kinetic energy (slower) left the reflectron first, the ions of higher kinetic energy (faster) have
time to catch up and reach the detector as one packet of ions rather than spread out spatially.
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2.3 Mass Spectrum Peak Identification
The process of electrospray ionization results in the production of multi-charged ions which
allows for large biomolecules to fall within the working range of most mass spectrometers. The
resultant x-axis for mass spectrometers is the mass-to-charge ratio which reflects the number of
charges a given molecule has obtained or lost during the ionization process. For instance, human
serum albumin (HSA) has a molecular weight of ~ 66,000 Da, but with the addition of 25 to 30
protons, results in an m/z ratio that is below 3000 and well within the working range of a variety
of mass analyzers.
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Figure 2.5. ESI-MS of human serum albumin depicted the multi-charged ions

The determination of the m/z value is related to the charge and the type of adduct formed with
the molecule. For a molecule of mass (M) it can have (n) number of charges, as well as an
additional adduct (ma)(Na+, K+ etc) and is expressed in the equation:
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m z = ( M + nma )
n

(eqn. 2.7)

The interpretation of large biomolecules with multiply charged peaks can be complicated. The
use of mathematical algorithms has aided in the determination of intact molecular masses. For
this particular software from Waters Corp. the MAXENT or maximum entropy algorithm was
used. The deconvoluted mass spectrum of the protein HSA depicted below shows the neutral
molecular mass of the intact HSA.
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Figure 2.6. Deconvoluted spectra of HSA showing the molecular ion mass
determined from the MaxEnt algorithm of the various charge states

Given the mass spectrum in figure 2.5, we can solve for the intact mass by using two adjacent
peaks in the spectrum. This is based on the assumption that the two peaks are from the same
intact mass and differ by the addition of only one proton. So for the m/z peaks at 2654.84 and
2553.08 we determine the intact mass as follows:
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The intact mass can be derived from equation 2.7 since the peak m/z ratios are given and we
assume two adjacent peaks are multiply charged ions differing by only one charge. Therefore:
2654.84 =

( M + nH + )
n

Assuming the lower m/z peak has (n +1) charges we assume:
2553.08 =

( M + ( n + 1) H + )
( n + 1)

Since the assumption was made that both peaks represent the same mass M = M.
n(2654.84) + nH+ = (n + 1)(2553.08) + (n + 1)H+
n(2654.84) = n(2553.08) + 2553.08 + H+
n(2654.84-2553.08) = 2553.08 + H+
2654.84n – 2553.08n = 2554.08
101.76n = 2554.08
n = 25
Putting that back into equation 2.7 gives the intact mass of the analyte:
2654.84 =

( M + 25)
25

so

66371 = M + 25

M = 66346
For smaller biomolecules that are examined by mass spectrometry the spectra are not as complex
and therefore do not need the rigorous treatment of mathematical algorithms to determine charge
state and molecular mass. The difference between isotopically resolved
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peaks can be used to determine the overall charge state. The spacing between the peaks is
indicative of the charge state: ∆m = 1Da is a single charged species, ∆m = 0.5 is double charged,
∆m = 0.33, and ∆m = 0.25 are triply and quadruply charged. For the spectrum
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Figure 2.7. ESI-MS of a small peptide illustrating the peak spacing for charge
state determination

shown in figure 2.7 of a zinc finger peptide (KGCWKCGKEGHQMKDCTER/Zn) the ∆m
spacing is 0.33, giving rise to a 3+ peak determination. The overall mass of the zinc finger
peptide can then be determined by:
M = n[(m/z) - H+]

(eqn. 2.7)

Where n = total number of charges and M = to the neutral mass.
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2.4 Fourier Transform Ion Cyclotron Resonance Mass Spectrometry
Fourier Transform Ion Cyclotron Resonance Mass Spectrometry (FTICR-MS), was
developed in 1974 by Comisarow and Marshall18-20 and was based on the fundamental theory of
ion cyclotron resonance introduced in the 1930’s by Lawrence and Edlefson. Electrospray was
first coupled with FTICR-MS in 1989 by Hunt, McLafferty, and coworkers thus allowing
researchers the ability to analyze large nonvolatile biomolecules with ultra high resolution.21
The coupling of ESI with FTICR-MS has proven advantageous because the resulting ions
formed typically have a mass-to-charge ratio between 500-2000, which falls within the working
mass range of the FTICR-MS.22
Figure 2.8 illustrates modified 4.7 Tesla FTICR-MS Ionspec Corporation (Irvine, CA)
with superconducting magnet used for all experiments in Chapter 6.23
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Figure 2.8 Modified Ionspec resistively heated Dual-ESI-FTICR-MS23
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Ions formed from the ESI process are desolvated in the heated metal capillary region and a small
portion sampled by the skimmer cone prior to accumulation in the hexapole.24 Hexapole
accumulation involves applying negative potentials to the hexapole endcaps to confine the ions
in the axial direction while also applying an r.f. only potential to confines the ions along the
radial direction of the hexapole.24 The stored ions are removed by applying a negative potential
to the entrance endcap and a more positive potential to the exit endcap. This method allows the
ions to be electrostatically “dumped” by the opening of a high speed shutter and guided through
the low pressure region by an r.f. only quadrupole ion guide prior to axial electrostatic trapping
inside the ICR cell.

A. Elongated Cubic Cell
X
5cm
Z

8cm

B. Cylindrical Cell
X

Y
5cm

6cm
Z

15cm

Y
6cm

Figure 2.9 ICR cell dimensions for A. Elongated and B. Cylindrical cell types
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For the experiments discussed in Chapter 6, a cylindrical ICR cell as shown in Figure 2.9B was
used. However, for simplicity in visualization, a cubic Penning ion trap, Figure 2.9A will be
discussed. A cubic ion trap consists of six flat stainless steel or gold coated plates arranged with
similar operating plates opposing. As shown in Figure 2.9 the six plates consist of two trapping
plates (5.1 cm x 5.1 cm), two excitation plates (5.1 cm x 7.7 cm), and two detection plates (5.1
cm x 7.7 cm). In order to obtain a mass spectrum with the FTICR-MS, a sequential series of
events must occur within the cell located inside the homogenous region of the superconducting
magnet at typical pressures of 1 x 10-10 Torr.
FTICR-MS involves using the plates in a sequential program of (1) quenching the ICR cell to
remove all ions, (2) trapping of ions, (3) excitation of trapped ions, and (4) detection of the
trapped ions. As ions enter the cell, the front trapping plate polarity is lowered to 0V for
approximately 2-3 ms to allow ions to freely enter the cell, while the back plate may be set to -5
to -10V for trapping. Once inside the cell, the front trapping plate is brought back to -10V, thus
creating a parabolic trapping well. Trapped ions experience a circular ion motion that is termed
the Lorentz force, perpendicular to the initial velocity and the field of the magnet.22,

25

The

frequency of this cyclotron motion is represented by equation 2.8,
vc =

zBO
2πm

2.8

where the frequency in Hertz of the cyclotron motion vc is calculated from the ions charge in
Coulombs, (z) the field strength of the magnet in Tesla (BO), and by the mass of the ion in
kilograms (m). Assuming the magnetic field strength remains constant, the frequency is thus
determined by the ion’s mass-to-charge ratio or m/z.
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The thermal cyclotron radius for a given ion entering the ICR cell is determined by
equation 2.9.

rthermal =

2mkT
zBO

2.9

where (m) is the mass of the ion, (k) is the Boltzman constant and (T) is the temperature in
Kelvin, (z) is the ion charge in Coulombs, and (BO) is the magnetic field strength in Tesla.
Following the trapping event and prior to detection, ions are excited to a radius that is
substantially larger than the thermal radius described above. The excitation plates, which are
parallel to the magnetic field, apply a frequency to the ions and thus alter the ions radius. During
this application, a large range of frequencies are scanned at once in a broadband excitation and
the trapped ions that are in resonance with the applied r.f. field absorb the energy and thus
increase its cyclotron radius while maintaining its cyclotron frequency.22, 26 This is represented
by equation 2.10.

rpost −excite =

V p − P Texcite
2dBO

2.10
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Figure 2.10 Schematic of ICR cell with Detection, Excitation, and
trapping plates labeled.
Where (Vp-p) represents the potential of the applied r.f. frequency in volts from peak to peak, (d)
is the diameter of the ICR or distance between the two plates of the cell in meters.
Once excited to the post-excitation radius, the ions are detected by the two detection plates in
parallel with the magnetic field. The detection plates are essentially electrodes and, as the ions
are rotating around the cell, they induce an image current by pushing/pulling electrons at the
plate interface. As this packet of ions moves away from one plate and toward another it
generates a sinusoidal pattern, as depicted in Figure 2.10, which is fast-Fourier transformed into
the frequency domain and then subsequently turned to the mass domain by solving equation 2.8.
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2.5 Mass spectrometry of biomolecules and metal containing ions
The binding of metal complexes to nucleic acids has been evaluated for more than 20 years.27
During that time, a variety of techniques including, NMR, ITC, CD, and MS have been used to
probe these interactions.27 Developing an understanding of exactly how these interactions occur
is beneficial to the development of new compounds. Noncovalent interactions between antitumor, anti-viral, and anti-bacterial compounds with DNA often serve as the precursor to DNA
damage or a cascade of interactions that alter the function or act as signaling mechanisms. The
use of ESI-MS has been used to study the interactions between DNA and a variety of metals
including, transition metals, alkali metals, and even actinide metals.28
A number of factors are important when using ESI-MS to investigate the metal-DNA
interactions. For instance, the sensitivity of the instrument may be reduced as there is an
inherent difficulty in removing the excess metal salts and the disruption of the ion current with
the sometimes numerous metal isotopes.28 Often, an instrument with high resolution is necessary
as metal compounds have very complex isotopic distributions.

The trinuclear platinum

complexes represented in this work are such an example. Finally, metal complexes tend to be
more labile during the MS/MS analysis, which make determination of binding sites difficult;
therefore enzymatic digestion is often is used.28
Using mass spectrometry, Gross and coworkers found that DNA exhibited a different
fragmentation profile when its phosphate backbone was complexed with metal ions.29 It was
determined that the addition of metal ions does not change the bonds that are cleaved during the
CID process, however, the usual lack of cleavage 3' to thymine is increased in the presence of a
bound metal ion.29
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The multitude of binding opportunities for metal ions with DNA presents a large number of
possible interactions with a variety of functional groups and heteroatoms. For instance, Mg2+
and K+ were shown to have relatively weak electrostatic associations with the phosphodiester
backbone of DNA.29, 30 However, even the weak association was found to play an important role
in the stabilization of the secondary and tertiary structures.30
A large portion of the research involving metal ions and biomolecules has been focused on the
interactions of platinum metals, which is not surprising, given the active role that platinum has
played in the treatment for cancer. The interaction of cisplatin with DNA has been extensively
studied via ESI-MS29 and therefore not discussed here. However, some important work looking
at the association constants of a [Pt(NH3)4]2+ with DNA has shown that a rapid interaction occurs
that was independent of the location and number of guanine bases.31 Just as important, the fact
that a much larger [Pt(py)4]2+ moiety exhibited less affinity indicated that the size and hydrogen
bonding of the ligands with the platinum center may play an important role in the determination
of the strength of the interaction.31
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Figure 2.11. ESI-FTICR-MS of BBR 3464 with DNA29

The covalent interactions of BBR 3464 with DNA, (figure 2.11) has been investigated using
ESI-FTICR-MS, which offers both sensitivity and high resolution.32

The utility of ESI-MS to

preserve the solution structures is seen in the presence of both mono and bi-functional adducts in
the interaction of BBR 3464, but also the strong electrostatic association of a AH 44, the
noncovalent equivalent compound.32 (see figure 3.2)
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Chapter 3:
Determination of binding site location of polynuclear platinum complexes
along the polyanionic phosphate backbone of DNA
3.1 Introduction
Mass spectrometry has been applied to a variety of different drug discovery approaches.1 The
abbreviated list includes: identification of drug metabolites, drug target identification, drug
screening, pharmacokinetics, and the covalent and noncovalent associations with biomolecules.1.
The usefulness of tandem mass spectrometry (ms/ms) as a tool for the characterization of
biopolymers such as DNA, is well established,2-5 and is based on both the accuracy of measuring
parent/product ions and the ability to derive structural information from unimolecular
dissociation chemistry.6

In instances where the nucleic acid is resistant to degradation by

enzymatic methods, ms/ms provides an excellent means of obtaining sequence information.7
The products produced from the fragmentation of DNA result from cleavage of the phosphate
backbone as first described by Grotjhan and co-workers in 1982.6,

8-10

McLuckey in 1992

devised a nomenclature scheme that resembled that of the naming scheme for peptides and
proteins.11,

12

The nomenclature depicted in figure 3.1 describes the four possible cleavage

products in relation to their orientation of the 5′ or 3′ terminus. The notation of a,b,c, and d
describe fragments that contain the 5′ terminus and the w,x,y, and z notation relates to fragments
containing the 3′ terminus. Sequence position is noted with numerical values and (B) represents a
nucleobase A,T,G, or C.
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Figure 3.1. McLuckey nomenclature for DNA cleavage.

During the CID process, the phosphate group has a strong effect on the metastable
decomposition and CID of the negatively charge nucleotides.6 For a series of small mono and
di-nucleotides, base loss from the 5′ terminus is almost always preferred over base loss from the
3′ terminus.6 The basicity of the nucleobases also has an impact on whether the resultant
fragmentation includes loss of the base as an ion or a neutral.6 The order of basicity for the
nucleobases is C- > T- > A- > G- when comparing the relative abundances of the BH elimination.6
Following an exhaustive set of experiments,13-15 McLuckey was able to establish the following
tendencies for single-stranded oligonucleotide fragmentations:

(1) the initial dissociation step results in the loss of a base which can be either charged or neutral
depending on the parent ion charge. Low charge state parent ions generally resulted in neutral
base loss and higher parent charge resulted in charged bases being formed.
(2) the 3′ terminus is usually disfavored in the loss of a base.
(3) the most important fragmentation step is the subsequent cleavage of the 3′ C-O bond of the
sugar from which the base is lost. This generally gives w and a-B type ions irrespective of
charge or nature of the base.
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(4) lower charge states generally result in more loss of the PO3- group and can compete for the
loss of the base.

3.2 Platinum Complex-DNA Interactions:
Investigations into the association and dissociation mechanisms of Pt drugs with DNA may
potentially lead to a better understanding of how these compounds exhibit their antitumor
properties. The soft ionization of electrospray coupled with mass spectrometry has enabled
research into the electrostatic outersphere associations between oligonucleotides and two mononuclear platinum species: platinum tetram(m)ine [Pt(NH3)4]2+ and platinum tetrapyridine
[Pt(py)4]2+.16 Tandem mass spectrometry (MS/MS) has proven to be a powerful tool in gathering
sequence information from nucleic acids, when there are difficulties in obtaining the data
through enzymatic digestion.7 Initial reports of MS/MS of platinated oligonucleotides date back
to 1991 by Martin et al17 and 1992 with Costello et al.18 In addition to cleavage of the glycosidic
bond of the oligonucleotide, the platinum sphere consistently lost the NH3 groups. It is noted
that the cleavage of the N-glycosidic bond is promoted when cisplatin is bound to the
oligonucleotide.17 Martin et. al. showed that platination helped stabilize the oligonucleotide and
results in a significant decrease in fragment ion abundance.7 Iannitti-Tito performed ms/ms
studies on a hexa-oligonucleotide with cisplatin and could not determine a sequence specific
fragmentation pattern.19
A detailed study of polybasic noncovalent binding complexes with DNA has shown that such
interactions can be identified using mass spectrometry.20 Furthermore, CID has proven to be
useful in the illustration of possible fragmentation pathways of an oligonucleotide complexed
with polybasic peptides.20
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3.3 Antisense Therapeutics:
Antisense oligonucleotides offer a promising therapeutic solution to selectively control gene
expression in certain cancers.

It has been previously shown that when Bcl-2 antisense

oligonucleotide therapy is used in conjunction with treatment of cisplatin in MCF-7 breast cancer
cells, cell viability decreases.21 Combination therapies involving cisplatin and Bcl-2 antisense
oligonucleotides have also shown some success in other types of cancer. In the bladder cancer
cell lines T24R1 and T24R2, the addition of the Bcl-2 antisense oligonucletotide was concluded
to reverse cisplatin resistance and amplify the cytoxity of the cisplatin.22

Recently, Bcl-2

antisense oligonucleotides with cisplatin therapy led up to an 80% cure rate in mice with
nasopharyngeal carcinoma.23
Antisense oligonucleotides are distinctive in that the chemical composition of the nucleotide
can be altered to render it more resistant to nuclease degradation in vivo. Currently, modified
oligonucleotides are being investigated in clinical trials for their antisense binding properties.
The most successful antisense oligonucleotides involve the modification of the phosphate
backbone of the oligonucleotide with a sulfur atom, currently marketed under the name G3139Genasense®.

This modification renders the oligonucleotide more resistant to nuclease

degradation, but it also has been shown to increase the cyctoxicity by nonspecific binding to
serum proteins. Additionally, it has been shown that modification of DNA with the addition of
cationic amino or guanidinum groups is successful in achieving an efficient antisense
oligonucleotide.24 Important as it relates to the research in this dissertation, the increased
stabilities of these structures were attributed to a localized region of reduced negative charge on
the antisense-guanidinium complex.24 Even with its success, antisense strategies have their
limitations and short comings, such as poor stability and low cellular uptake. It has been
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reported that cellular uptake of the oligonucleotide can be < 2% of the initial dose depending on
the specific type of oligonucleotide chemical composition and certain cell types.25-27
The use of noncovalently bound platinum compounds to provide increased stability allows for
a native DNA backbone structure that may result in less cytotoxicity issues. Also, the addition of
the highly charged platinum compound may enhance cellular uptake. Our group has recently
shown that the use of these highly charged (4+ to 6+) polynuclear platinum compounds
successfully stabilized calf thymus DNA by increasing the melting temperature by as much as
20°C.28 We have also shown that the cellular accumulation of the “noncovalent” polynuclear
platinum compound is about 5 times greater than the covalent parent compound BBR 3464 in
A2780 human ovarian tumor cell lines.29
In this current investigation we have chosen to study the gas-phase stability of the
oligonucleotide-platinum complex using electrospray ionization mass spectrometry (ESI-TOFMS/MS). For the work presented in this chapter we studied a synthetic mimic of the 18-mer
oligonucleotide

antisense

sequence

specific

for

the

Bcl-2

mRNA

(5`-

TCTCCCAGCGTGCGCCAT-3`) currently used in clinical trials by Genta, not containing the
modified phosphothiorate oligonucleotide backbone. The synthetic oligonucleotide purchased
did not have the modified backbone. Aside from a fundamental interest, this study deals with a
model of DNA that is of great interest in antisense gene therapy.
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3.4 Experimental:
Experiments were conducted on a Micromass-Waters Qtof-2 mass spectrometer (Milford, MA)
equipped with a custom built microspray source. Electrospray source conditions were kept
constant with a source temperature of 120°C, capillary voltage of 2.0 kV, cone voltage 38 V, and
flow rates of 0.5 µL/min. In tandem mass spectrometry (MS/MS) experiments, collisional
energy was varied from 10 eV to 40 eV. The use of translational energy to represent the applied
collisional energy in this work was chosen so that comparisons could be made between
complexes of differing charge states. The translational energy is the product of the ions charge
state and the applied collisional voltage.
The oligonucleotide 5′-TCT CCC AGC GTG CGC CAT-3′ (M= 5411.5 Da) was purchased
from Midland Certified Reagents, (Midland, TX) and further desalted in a custom built dialysis
chamber using hollow 13,000 molecular weight cut off (MWCO) filters in 20 mM ammonium
acetate. The dialysis of the oligonucleotide in ammonium acetate results in displacement of Na+
and K+ ions from the anionic backbone and replacement with NH4+ ions.

During the

electrospray desolvation process the NH4+ loses a proton and NH3 is lost as a neutral molecule.
The dialyzed oligonucleotides are now relatively salt free making for a cleaner mass spectrum.
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Oligonucleotides were reconstituted in 18 Ω ohm water and quantified by UV-VIS at 260 nm.
Noncovalent polynuclear platinum compounds AH 88 (M = 608 Da) and AH 44 (M = 953 Da)
were synthesized in house and purified using HPLC.28
A stock solution of 500 uM Pt compound was prepared in 18 Ω ohm water. Oligonucleotides
and Pt compounds were mixed in a 1:1 molar ratio and incubated at 37°C for 20 minutes then
mixed with electrospray solution to form 50:50 methanol:20 mM ammonium acetate. Full scan
and tandem MS/MS data were analyzed using MassLynx 4.0 software.

3.5 Results and Discussion:
Detection of Noncovalent Complexes:
Herein we describe the detection by ESI-TOF-MS of noncovalent complexes between
polynuclear platinum anticancer compounds with an antisense oligonucleotide sequence. As we
expect these complexes to be negatively charged in solution, all spectra were obtained in
negative ionization mode. Figure 3.3 (A) and (B) show the full scan spectra of AH 88 (4+) and
AH 44 (6+) electrostatically interacting with the 18-mer oligonucleotide, respectively. Free
oligonucleotide, present in each spectra with charge states ranging from four to six negative
charges and oligonucleotide:polynuclear platinum complexes with the same four to six negative
charge states. The absence of the free platinum compound is expected in the negative ionization
mode, as they have a high positive charge and no acidic groups to deprotonate and therefore are
unlikely to be detected.

Given the high charge and size of these polynuclear platinum

complexes, the most abundant stoichiometry observed was 1:1. It should be noted that the much
smaller and lesser charged AH 88 (4+)is capable of forming a 1:2 binding ratio under these
conditions with the 18-mer oligonucleotide, but is only represented at approximately 5% of the
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relative abundance(see figure 3.3 A). The addition of two AH 88 platinum compounds of this
size and charge, presumably still results in the remaining phosphate groups of the
oligonucleotide retaining sufficient negative charge for detection. The high charge of AH 44
would most likely result in coulombic repulsions of two platinum compounds on the single
strand and is unlikely to exist during the ESI desolvation process, not to say that it cannot exist in
solution. It should be noted that the ammonium acetate concentration of 20mM was adequate for
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the detection of these electrostatic complexes. Terrier and co-workers have recently shown that
polybasic compounds interacting electrostatically with oligonucleotides are ionic in solution and
therefore compete with ammonium ions from the ammonium acetate for phosphate residues.20
During this research, no effort was made to quantitatively determine the binding affinities of
these complexes or reaction rates. Mass spectrometry, while extremely useful, can present
problems when comparing complexes of different size and structure due to the differences in
ionization potentials, leading to misleading results. In addition, for research in probing
electrostatic interactions between complexes, the species represented in solution may not always
transfer to the gas phase in the same proportions. Therefore, this study focuses on the gas phase
stability of the complexes formed between the novel polynuclear platinum compounds and the
phosphates of an oligonucleotide.
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Figure 3.4 ESI-MS/MS spectra of (A) (Oligo)4-, (B) (Oligo+AH 88)4-, (C) (Oligo
+AH44)4-. Translational energies are (A) 100 eV, (B) 120 eV, and (C) 120 eV.

56
Collision Induced Dissociation (CID)
Tandem mass spectrometry experiments were done on free oligonucleotide, and then with the
electrostatic complexes of oligonucleotide with AH 88 and AH 44. For each system two charge
states, the 4- and 5-, were studied in efforts to see how higher charge distributions affected the
fragmentation profile. The CID investigations were done at progressively higher translational
energies up to the point where the parent ion was completely dissociated or removed from the
spectrum. As these samples were introduced into the mass spectrometer in negative ionization
mode, the lack of negatively charged polynuclear platinum complexes in the full scan spectra
was expected.

Tandem mass spectrometry experiments of the “free” oligonucleotides and the

complexed oligonucleotides allowed for the determination of an approximate binding location
along the phosphate backbone.

Using McLuckey nomenclature for oligonucleotide

fragmentation, we were able to determine that these polynuclear platinum complexes increase
the overall stability of the phosphate backbone along the interior nucleotides and do not alter the
dominant fragmentation mechanism of producing a and w type ions. Additionally, we have used
mass spectrometry to rapidly identify the binding site location for a polynuclear platinum
compound on the phosphate backbone.

Free Oligonucleotide.
The CID products of the free unbound 18-mer oligonucleotide in Figure 3.4 were representative
of covalent bond cleavage of the phosphodiester backbone. Sequence fragment ions produced at
the different translation energies were of the an-B and wn type, according to McLuckey
nomenclature. As shown in Figure 3.5, the fragmentation of the 4- free oligonucleotide (A) at
m/z 1352 and at 100 eV of translational energy, covers nearly complete fragmentation. The
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spectra in Figure 3.4 represents the translational energy at which approximately 50% of the
parent ion exists in the spectra.
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Figure 3.5 McLuckey fragmentation profile of free oligo at 100V of translational
energy. Nearly complete fragmentation of the backbone is observed allowing for
all peak assignments

The plot of fragment ions illustrates that approximately equal distribution of a-type and w-type
ions exists. Nearly complete sequence coverage was achieved with the only fragments that do
not appear in the spectra being those from the 3′- side of the thymine base. This correlates well
with known DNA fragmentation data in that the 3′- side of the thymine base is not readily seen
as a w-type ion. Careful inspection of the data, show peaks at 466 m/z and 481 m/z that are
internal fragment ions of the oligonucleotide. These peaks occur at the higher translational
energies and are therefore due to the higher energies involved or the possible result of secondary
fragmentations. The relative abundances for all the ions produced are displayed in the histogram
in Figure 3.6. As is expected, higher translational energies led to more sequence coverage.
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Figure 3.6 Relative intensity plot of free a-B/w-ions of free
oligonucleotide at varying translational energy (A) 100 eV, (B) 120 ev,
(C) 140 eV. Internal fragments omitted from data.
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Polynuclear platinum compound AH 884+.
In the CID spectrum (Figure 3.5 B) of the (oligo+AH 88)4- at 120 eV translational energy, the
product ions produced are still of the a-B and w-type ions. Upon, further review of the spectra, a
peak at 1081 m/z appears which would correspond to the 5- intact free 18-mer oligonucleotide.
This was unexpected as a shift to lower charge states is normally observed during the CID
process as intact molecules lose a charged fragment and therefore shift to a higher mass-tocharge ratio. This fragment ion was produced from the noncovalent dissociation of the AH 88
from the oligonucleotide. It is reasonable to believe that the gas phase interaction of the amines
on the platinum compound with the phosphate resulted in a region of neutral charge with a
hydrogen bond being formed between the two species. Upon CID, the the hydrogen bond
between the phosphate and amines is broken and the proton remains on the platinum moiety.
The stabilizing effects of the highly charged cationic platinum complex when noncovalently
attached to the 18-mer oligonucleotide over the “free” 18-mer oligonucleotide are seen in the
increase in collision energy necessary to induce backbone cleavage of the oligonucleotide.
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Figure 3.7. CID fragmentation of (oligo+AH88)4- at 120 eV translational
energy. Region of enhanced stability highlighted
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Figure3.8 Relative Intensity plot of the 4- AH 88/18-mer complex aB/w ions produced by CID of free 18-mer oligonucleotide. (A) 100 eV
(B) 120 eV (C) 140 eV translational energy.
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Polynuclear platinum compound AH 446+.
The Figure 3.4 (C) displays the spectrum of (oligo+AH 44)4- Pt complex at 1590 m/z and 120
eV of translational energy. The number and intensity of product ions observed are noticeably less
for this translational energy. Unlike the fragmentation for the dinuclear AH 884+, there is no
remaining free oliognucleotide as the result of a noncovalent dissociation pathway. Again, due to
the lack of acidic sites, the polynuclear platinum comound does not bear a negative charge and is
thus not observed. The increase in overall stability is noticeable in the presence of remaining
oligonucleotide/Pt complex in the spectra. Upon further investigation of the sequence coverage
6 5 4 3 2
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5´ -T C T C C C A G C G T G C G C C A T - 3´
a

2

4

6

Figure 3.9 Oligo+AH 44 fragmentation profile. The area highlighted
in red represents the portion of the oligo that was not identifiable in
the spectra. The absence represents the presumed binding site for AH
44.
with the Pt adducts reveals that an intact five-nucleobase stretch in the internal sequence of the
bases exists. The increase in collision energy is representative of the increased stability of the
phosphate backbone via the hydrogen bonding of the AH 44 trinuclear platinum complex. The
location of increased stability represents five potential phosphates for which the Pt adduct may
have been located. We know from crystallographic data that our trinuclear complexes are
capable of spanning three phosphate groups in a backbone tracking binding motif.30 This would
point to the overall charge of 6+ from the AH 44 neutralizing the five phosphate groups, and thus
remain undetected in the spectra. The disappearance of the complex and no free AH 44 or
fragments containing the complex indicates that the AH 44 most likely bears no charge within
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the complex. The missing portion of the sequence would effectively have zero charge and not be
visible in the negative ion spectra. At no point during the CID process were there any observable
free oligonucleotide peaks, further illustrating the strong interaction of the AH 44 with the
phosphate backbone.
Positive ESI-MS/MS of the 18-mer oligonucleotide with AH 44 and 88 were conducted to
determine if an oligonucleotide fragment complexed with the AH 44 could be detected (Data not
shown). The results however, failed to provide any detail of binding site location and more
importantly, the presence of free AH 44 was not detected either. These results were unexpected
as the positive ionization mode should provide a spectrum of the cationic AH 44 and 88. The
most plausible explanation is that upon interaction of the AH 44 and 88 with the phosphate
backbone a neutral region is formed and because of the stability of the phosphate clamp there is
no discernible dissociation.

63

AH 4 4 - 18 me r 4 - 2 5 V

A

0.3

Relavtive Intensity

0.25

an-B 1-

0.2

an-B 2-

0.15

wn 1-

0.1

wn 2-

0.05

0
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

n fr a g me n t a t io n

AH4 4 - 18 me r 3 0 V 4 -

B

0.25

an-B 1-

Relavtive Intensity

0.2

an-B 2-

0.15

wn 10.1

wn 20.05

0
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

n fr a g me n t a t io n

AH 4 4 - 18 me r 3 5 V 4 -

C

0.25

an-B 1-

Relavtive Intensity

0.2

an-B 2-

0.15

wn 10.1

wn 20.05

0
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

n fr a g me n t a t io n

Figure 3.10 Relative Intensity plot of the 4- AH 44/18-mer complex
a-B/w ions produced by CID of free 18-mer oligonucleotide. (A) 100
eV (B) 120 eV (C) 140 eV translational energy. Internal fragment
ions not included in graphs
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Fragmentation pathway for oligonucleotide-polynuclear platinum complexes.
Based on the observed fragmentation patterns and binding site location of these noncovalent
complexes, we propose two possible fragmentation pathways occurring in the gas phase, Figure
3.11. Pathway 1A involves the noncovalent dissociation of the platinum moiety from the intact
oligonucleotide which is then preceded by pathway 1B where secondary fragmentations result in
the production of the a-B and w type ions. As seen in the CID spectra of the (oligo+AH88)4-,
only a small fraction of the complex exhibits this dissociation pathway, but we feel that it is
important to mention.

1A

1B

A1

2B
+

B2

+

2A
2C
+

+

Figure 3.11. Schematic of possible dissociation pathways for the
fragmentation of noncovalent platinum complexed oligonucleotides
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This pathway is more likely for polybasic compounds that have the ability to carry a negative
charge upon dissociation, as the increase in negative repulsion between the oligonucleotide and
compound would make noncovalent dissociation favorable. In our case, the platinum species will
most likely come off as a neutral, but the possibility still exists. Pathway 2A represents a more
favorable dissociation scheme for these highly charged and extremely stable platinum-DNA
compounds. First, because these oligo+Pt complexes are so stable, noncovalent dissociation is
unfavored and covalent cleavage of the phosphodiester backbone is the primary pathway. As
seen in the CID experiments, small singly charged oligonucleotide a-B and w-type fragments
dominate the spectra. This is indicative of the cleavages occurring on either side of the stabilized
region of platinum binding. As only four available charges are present on either side, we get
mainly single charged fragments until we increase the translational energy to 140 eV. Pathway
2B would only be likely to occur if secondary collisions were to noncovalently dissociate the
complex from the now smaller oligo fragment + platinum compound. We do not see any
evidence of larger sequence ions in the spectra that would correlate to pathway 2B. Lastly,
pathway 2C depicts the possibility of secondary collisions cleaving the remaining phosphodiester
backbone leaving the remaining platinum bound region unfragmented and undetectable by mass
spectrometry as it does not carry a charge.

3.6 Conclusions
The results presented in this work show that the electrostatic interaction between highly charged
polynuclear platinum complexes and single stranded oligonucleotides is extremely strong in the
gas phase. The high stability of the interactions between the phosphate groups and the platinum
complexes was confirmed by the dominant covalent fragmentation pathway observed. Only the
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small AH 884+ resulted in a minimal amount of noncovalent dissociation to produce free single
stranded oligonucleotide. The increase in size and charge of AH 446+ did not promote the
noncovalent dissocation as the stability of the overall complex with the additional hydrogen
bonding was greater. Upon inspection of the higher translational energy spectra, it is apparent
that the overall complex is losing ~ 17 mass units, which may correspond to the fragmentation of
the NH3 ligands on the platinum compound. Indeed, Schaff and coworkers have identified the
loss of NH3 during the ESI surface collision induced dissociation experiments from both cis and
trans dinuclear platinum complexes.31
It is noteworthy to illustrate that no peak in the spectrum corresponds to loss of the Pt adduct
from the intact oligonucleotide. The lack of coulombic repulsions between the AH compounds
and the oligonucleotide create a region of increased stability that must be overcome and therefore
the pathway that dominates the CID spectra is the covalent fragmentation of the backbone. The
lack of charge between the areas of interaction between the two is further illustrated in the
absence of any Pt adducted oligonucleotide fragments. Finally, we have used mass spectrometry
as a rapid and efficient means to determine the approximate binding site location of noncovalent
polynuclear platinum compounds on an oligonucleotide. This provides a much simpler method
of identification in comparison to other tedious methods such NMR and enzymatic cleavage.
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Chapter 4:
Duplex DNA Stabilization and evidence for phosphate binding
4.1 Introduction
Mass spectrometry is an essential tool in the drug development process, with an indispensable
involvement in many of the key steps of identifying new therapeutics, compound purity,
toxicology, and pharmacokinetics.3 The investigation of noncovalent complexes between DNA,
proteins, and peptides with a variety of synthetic and biologically relevant structures has become
increasingly more common with the coupling of electrospray ionization and mass spectrometry
(ESI-MS). Two ways in which investigations into noncovalent associations have benefited from
mass spectrometry are: 1. the use of a full scan MS to obtain a relative stoichiometry of the
complexes that are present in solution and also make inferences on their relative abundances, and
2. tandem mass spectrometry (MS/MS) or MSn allows the gas phase stabilities between the two
complexes to be examined.4

Mass spectrometry is an ideal experimental method for the

characterization of pure intermolecular interactions because it can be conducted free from any
interfering solvent.5, 6 The first published paper detailing the characterization of noncovalently
interacting biomolecules in the gas phase following ESI was reported in 1991 by Ganem et al.7
Since that time, a review of the literature shows a publication record of ~500 research and review
articles dealing with the detection or characterization of noncovalent biomolecular complexes.
ESI-MS offers several advantages over traditional methods of noncovalent characterizations3,
such as: (1) the interacting compounds do not have to be modified with special probes or labels.
This maintains the native shape or structure of the species to be studied and doesn’t alter their
binding properties; (2) minimal amounts of sample are needed to perform an analysis,
microgram quantities in comparison to milligram amounts for NMR and crystallography; (3)
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sample purity is ideal, but not imperative in the study of noncovalent complexes because the data
is separated on a mass scale. This ability to detect a mass shift from expected results allows the
identification of degradation products or intermediates and gives the researcher the ability to
select which products to investigate further.

4.2 Noncovalent Interactions on DNA
Biological events involving DNA interacting with small molecular ligands, metal ions, and
proteins, are crucial for the regulation of such processes as transcription and replication.

8

The

interactions between the biomolecules may be either noncovalent, and therefore reversible, or
irreversible through covalent modifications or coordinative binding with metal complexes.8
Duplex DNA with its negative phosphate groups, formation of major and minor grooves, and the
planar nucleobase structures, offer numerous possible binding sites for the interaction of
noncovalent compounds.

These types of interactions involving small molecules are

characterized as; (1) electrostatic interactions between the negative phosphate backbone and
cationic metal complexes or charged organic molecules, (2) hydrogen-bond interactions between
minor/major groove binders, and (3) intercalation, where extended planar ligands insert between
adjacent base pairs and associate via π-stacking interactions.8 Examples are shown in Figure 4.1,
as representative structures for minor groove binders and intercalators, respectively. Minor
groove binders are generally curved or bent and usually have an associated positive charge.
They are able to insert into the minor groove without distorting the shape of the double helix.5
Minor groove binders, such as the ones shown in Figure 4.1(A) show a sequence specificity for
AT-rich regions in duplex DNA. This preference for AT regions is related to three factors: (a)
AT regions have more negative electrostatic potential, which are favorable for positively charged
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Figure 4.1. Commonly studied minor groove binders and intercalators

compounds; (b) the narrowness of the AT-rich minor groove allows for favorable contacts with
the sugar moieties, and (c) GC regions of the duplex have an –NH2 of guanine on the floor of the
groove which adds steric hinderance.5 Intercalators by comparison, are represented by planar
aromatic or heterocyclic ring systems that interact with duplex DNA by inserting themselves and
stacking between base pairs.9, 10 Unlike minor groove binders, intercalators perturb the DNA
duplex structure as the helix must unwind to form the intercalation site.5 The consequence of
these interactions through hydrogen bonding, van der Waals, hydrophobic and electrostatic
forces, can result in an overall stabilizing effect on the DNA.9, 11, 12
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4.3 Noncovalent polynuclear platinum complexes with DNA
Noncovalent interactions between biomolecules and antitumor complexes play an important role
in a therapeutics mechanism of action.

In the case of the clinically relevant polynuclear

compound, BBR 3464, the covalent binding process is preceded by an initial noncovalent
association with the duplex DNA sequence.2 The presence of a charged moiety in the form
of a platinum tetraamine significantly enhances the potency over a neutral linker such as
hexane.2, 13
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Figure 4.2 Electrostatic interaction of BBR 3464 with duplex DNA 2

Recently, we have shown that highly charged cationic trinuclear platinum compounds with
varied overall charge (+6 to +8), have increased cellular accumulation in A2780 human ovarian
tumor cells, by as much as five times their covalent analog BBR 3464, currently in Phase II
clinical trials14. The surprising increase in cellular accumulation by cells and cytotoxicity may
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be due to the unique structure/charge relationship of these compounds. X-ray crystallography has
revealed a possible third mode of DNA binding, the “phosphate clamp”, involving the +8
trinuclear platinum compound shown in Figure 4.3.15 The phosphate clamp was shown to form
via the three square planar tetra-am(m)ine Pt (II) coordination units using a bidentate
coordination preferentially with the O2 phosphate oxygens. Crystallographic data shows two
distinct modes of binding to DNA: 1. groove spanning and 2. backbone tracking.15 This type of
Pt(NH3)3 – phosphate binding is similar to the guanidinium - phosphate moieties found in
numerous biological complexes. The focus of this research was to investigate the gas phase
stability of oligonucleotides complexed with the “phosphate clamp” DNA binding motif. We
used

the

highly

charged

+6

trinuclear

platinum

complex

[{Pt(NH3)3}2-µ-trans-

Pt(NH3)2(NH2(CH2)6NH3)2 and the +8 dangling amine (DA) polynuclear platinum complex
[{trans-Pt(NH3)3}2(NH2)(CH2)6(NH3+)}2-µ-trans-Pt(NH3)2(NH2(CH2)6NH2)2] (Figure 4.8). These
noncovalent platinum compounds are structurally similar to our clinically relevant, covalent
binding BBR 3464, expect for the replacement of the labile chloride ligands with nonlabile
ammines and hexane-diamines, respectively. The presence of the additional amine ligands
increases the overall charge and hydrogen bonding capabilities of these compounds to the
negatively charged phosphate backbone of nucleic acids.
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Figure 4.3 X-ray crystal structure of noncovalent platinum complexes forming phosphate
clamp interactions with DNA.15
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4.4 Experimental
Experiments were conducted on a Micromass-Waters Qtof-2 mass spectrometer (Milford, MA)
equipped with a custom built microspray source. Electrospray source conditions were kept
constant with a source temperature of 120°C, capillary voltage of 2.0 kV, cone voltage 38 V, and
flow rates of 0.5 µL/min. In tandem mass spectrometry (MS/MS) experiments, collisional
energy was varied from 10 eV to 40 eV. The oligonucleotides 5′-TAG CGC TTT TTC GCG TA
-3′ (M= 5167 Da) and 5′- TA CGC GAA AAA GCG CTA -3′ (M= 5212 Da) was purchased
from Midland Certified Reagents, (Midland, TX) and further desalted in a custom built dialysis
chamber using hollow 13,000 molecular weight cut off (MWCO) filters in 20 mM ammonium
acetate. Equimolar solutions of oligonucleotides were annealed in 20mM ammonium acetate at
90º C for 5 minutes and allowed to cool to room temperature. A stock solution of 500 uM Pt
compound was prepared in 18 Ω ohm water. Oligonucleotides and Pt compounds were mixed in
a 1:1 molar ratio and incubated at 37°C for 20 minutes then mixed with electrospray solution to
form 50:50 methanol:20 mM ammonium acetate. Full scan and tandem MS/MS data were
analyzed using MassLynx 4.0 software.

4.5. Results and Discussion
Electrospray ionization time of flight mass spectrometry (ESI-TOF-MS) and collision-induced
dissociation (CID) were used to investigate the gas phase stability of synthetic oligonucleotides
complexed with the highly charged noncovalent polynuclear platinum compound. Investigations
into the gas phase stability of duplex DNA-drug complexes have previously been studied for
intercalators and minor groove binders[#97]5, 9,

12, 16-18

, but this is the first reported gas phase

78
study of a platinum phosphate clamp style DNA-drug interaction with duplex DNA. As this new
binding mechanism represents a novel approach to cancer therapeutics, a systematic study of the
different complexes was undertaken. Only recently has the application of mass spectrometry and
CID been reported for the characterization of these types of salt bridge interactions, such as those
between arginine forks and phosphate groups.19-23

Shown in Figure 4.4, the nature and

orientation of the platinum phosphate clamp is very similar to the arginine forks formed between
the guanidinium group of peptides and anionic structures such as phosphates, sulfonates, and
carboxylates.

Studies by Schug and Lindner have shown that phosphonate and sulfonate

functionalized amino acid complexes display a higher rate of complexation when compared to
carboxylate functionalized amino acids.22, 23 Despite the lower propensity to form a guanidiniumcarboxylate complex, gas phase CID showed a much higher energy for dissociation in
comparison to the phosponate and sulfonate functionalized complexes.11, 22
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Figure 4.4 Structural similarity of the arginine fork found in nature with the
platinum phosphate clamp motif
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4.6 CID of DNA-Drug complexes
As mentioned earlier, the interaction of drugs with DNA can be classified in two general
categories, intercalators and minor groove binders. In addition to how they interact with DNA,
drugs can also be categorized by their dissociation pathway with DNA during the CID process.
Rosu and coworkers have formed a general description for this compound specific dissociation
pathway5 The first pathway represented by intercalators results in the loss of the drug as a
neutral species upon CID resulting in free duplex DNA remaining. (Figure 4.5) It should be
noted that the size and sequence of the duplex DNA can also result in strand separation and
therefore free duplex is not always the CID product when dealing with intercalators.5

[complex]7-

[duplex]7-

+

[drug]

Figure 4.5 Neutral drug loss from the complex upon
CID
Figure 4.5 shows the fragmentation pathway in which the DNA-drug complex dissociates with
the loss of a negatively charged drug from the complex. These types of pathways depend on the
drugs ability to give up a proton to the DNA.

[complex]7-

[duplex]6-

+

[drug]-

Figure 4.6 Dissociation resulting in loss of a charged
drug and remaining duplex

The third and final dissociation pathway, shown in Figure 4.6, results in the separation of the
duplex DNA structure into its single strand components, with each strand sharing the available
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charge of the intact duplex.5 The drug molecule generally remains bound to one or both strands
upon CID.

This type of fragmentation profile is representative of the positively charged

intercalator ethidium bromide and all minor groove binders.5

For those compounds

characterized by the dissociation pathway in Figure 4.5, the ability to lose the drug as a neutral
from this fragmentation pathway also exists and is sometimes seen for the minor groove binders
Hoechsts 33258 and 33342.5 As has been mentioned by Rosu et al, the stability of a DNA-Drug
complex can be compared directly to the stability of the DNA duplex alone by comparing the
differences in CID energies5

In addition, they have also determined that key structural

differences in the drugs may play a part in the perceived stability increases, such as the ability to
form a higher number of hydrogen bonds with the duplex, and overall charge of the drug.5

1
[complex]

[ss+drug]3-

+

[ss]4-

[ss+drug]4-

+

[ss]3-

7-

2

Figure 4.7 Fragmentation pathway exhibited by minor groove
binders.
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4.7 CID of Duplex DNA-Platinum Complexes
In efforts to investigate the potential effects of the phosphate clamp motif, a series of
noncovalent polynuclear platinum compounds were chosen based on their ability to interact with
DNA. Figure 4.8 shows the five structurally distinct platinum compounds used in this study,
with each compound allowing for comparisons to be made about charge and hydrogen bonding
character. The compounds represented above vary in both charge state (4+) for compound (A);
(6+) for compounds (B-D); and (8+) for compound (E), and hydrogen bonding character with
variation in the central linker.
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Figure 4.8 Polynuclear platinum compounds. (A) AH 88, (B) AH 59, (C) AH 44, (D)
AH 48, and (E) AH 78

NH3
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It has been established that the presence of a central platinum moiety plays a critical role in the
pre-association with biomolecules.2 Compounds (B-D) all possess a high 6+ charge, but differ in
their potential to interact with the duplex DNA. Compound (B) AH 59, is a dinuclear compound
separated by a charge spermine linker. Compound (C) AH 44 and compound (D) AH 48 are
both trinuclear compounds with a central platinum moiety, but differ in the two outer platinums
with the presence of dien in AH 48. The rationale in comparing (C) and (D) is that the dien
structures should limit the ability to form the phosphate clamp and therefore result in a weaker
interaction.

Additionally, the comparison with a known minor grove binder, Hoechst 33258,

was used to determine if these compounds altered the fragmentation pattern.
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Figure 4.9 Free 17-mer duplex CID at increasing collisional energy

Figure 4.9, represents the 7- charge state of the free 17-mer duplex at increasingly higher
collisional voltages with the 16V of collisional energy representing the CE50% which is roughly
the point at which 50% of the duplex remains intact. Upon CID of the 7- charge state at 1482
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m/z, strand separation with the seven available charges being distributed among them is seen.
Due to the high charge state chosen for the CID, there is no covalent backbone cleavage
observed as the higher charge aids in the coulombic repulsion of the two strands. As a result, the
duplex separates into the 3- and 4- single strand constituents. This is consistent with the
described mechanism of duplex dissociation as described above by Rosu.5
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Figure 4.10 17-mer duplex complexes in a 1:1 ratio with Hoechst dye CID at
increasing collisional energy

The CID of Hoechst dye with duplex DNA has been characterized extensively in the literature.
As is the case with all known minor groove binders, the dissociation proceeds with strand
separation with the drug being able to remain bound to either of the two strands. In the CID
fragmentation of minor groove binders, the increase in the hexapole collision energy applied that
is needed to fragment the complex, indicates that the complex is more stable than the free DNA
alone.
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Figure 4.11 17-mer duplex with AH 88 in a 1:1 ratio CID at increasing
collisional energy

The addition of hydrogen bonds between the two are thought to add to increased stabilization,
but also the number of positive charges carried by the drug increases the electrostatic
interactions.5 Due to the small nature and low charge for the Hoechst dye, we can see the
fragmentation pathway allows for the drug to be on both the lower and higher charged single
strand formed after the CID experiment. As seen in Figure 4.10, the CID of the peak at 1543 m/z
yields strand separation into both the free 3- and 4- single strand products as well as the 3- and 4ss+Hoechst dye peaks. The additional hydrogen bonding provided by the Hoechst dye as well as
the positive charge have been associated with an increase in the stabilization energies.5

The addition of the 4+ dinuclear platinum compound AH 88, reveals a slight increase in the
overall duplex stability of the 17-mer over that of the Hoechst dye as seen in Figure 4.11. Given
that the platinum compound has an increased positive charge over the Hoechst dye this may be
the contributing factor. The complex with AH 88 is kinetically more stable as it forms more
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hydrogen bonds with the DNA as well as having additional charge ~ 3+. The dissociation
channel of the duplex when bound with the platinum compound is still representative of Figure
4.7, where single strand separation is the main dissociation pathway. The CID of 1568 m/z
reveals that at the highest collisional energy used some free 3- ssDNA is starting to appear. As
described above this is likely due to the neutral loss of the platinum compound. Since the
platinum compound will still have some positive charge, the negative ion detection mode will
not reveal the free platinum moiety.
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Figure 4.12 CID of 17-mer duplex with (A) AH 59, (B) AH 48, (C) AH 44 at
increasing collisional energy

87
Charge state comparision
To investigate the effect that the size and hydrogen bonding ability have on the stability of
duplex DNA three compounds: AH 59, AH 44, and AH 48 were investigated. Each of these
compounds possesses a high charge with all being 6+, but they differ in the possible ways they
may interact with the phosphate backbone of the DNA. AH 59 is a dinuclear compound that is
separated by a spermine linker, AH 44 is a trinuclear compound, and AH 48 is a trinuclear
compound that has a dien structure on the outer platinum centers. This addition of the dien
structure should result in less ability to form the phosphate clamp binding motif and therefore,
maybe the potential for a lower stabilizing effect. As mentioned earlier, the central platinum
moiety is essential in making the pre-association contacts with DNA. Recently, the crystal
structure of AH 59 with the Dickerson Drew Dodecomer (DDD) revealed that the AH 59 bridged
the two duplex strands making hydrogen bond contacts through the terminal amine and the
spermine NH2. The comparison of the AH 44 with AH 59 reveals that the increased stability of
the AH 44 over that of AH 59 is greatly enhanced, possibly by the stability added through the
additional hydrogen bond contacts. As the charge and therefore electrostatic component of these
two compounds are the same, the additional stability must be attributable to the central linker
portion of the compound. Comparison of the stabilities between AH 44 and AH 48 reveal nearly
identical CE50% values. This may give some indication that the terminal platinum structures are
involved, but to a lesser degree than the central portion of the compound. In the case for all three
of these compounds, the stabilities and associations are strong enough that no free 3- ssDNA
exists in the spectra.
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Figure 4.13. CID of 17-mer duplex with AH 78 at increasing collisional energy

When comparing the trinuclear compounds they both appear to be very similar in stabilizing
potential. The addition of the dien structures does not appear to greatly alter the stabilizing
effects of the compound. When compared with the dinuclear complex of the same charge, the
addition of the central platinum moiety may play an essential role in the stabilizing effect. It was
originally conceived that the dien structures would limit the phosphate clamp motif and therefore
result in a lower CE50% value, however, that has not proven to be the case. Based on crystal
structure data of the trinuclear compounds, the central platinum moiety is involved in the
phosphate clamp binding motif, adding strength to the argument. Additionally, NMR studies of
the covalent trinuclear compound BBR 3464 shows that the central platinum makes an
immediate association with the DNA.2
The greatest overall stability for these types of compounds was found to be exhibited by the large
8+ trinuclear compound AH78. Increasing the charge to 8+ and adding an aminohexane linker
to the terminal platinum centers dramatically increases the overall duplex stability.

The

combined positive charge with the multiple hydrogen bonding ligands offers a profound effect
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on the stabilization of duplex DNA. Seen in Figure 4.13, and illustrated in the dissociation
energy plot in Figure 4.14, the CE50% is extended over the other compounds to ~30V of
collisional energy.

Strand separation is still the preferred dissociation pathway for this

compound as well, which may hint to a common characteristic for this type of new phosphate
clamp binding motif.
A duplex dissociation curve is shown in Figure 4.14, comparing the gas phase duplex stability
versus the applied hexapole collision energy. The plot reveals the trend of increasingly higher
stabilities with increasing platinum compound size, charge, and hydrogen bonding ability. For
the two compounds AH 44 and AH 48, the plot reveals very similar dissociation profiles. This
was somewhat unexpected as the two should have different hydrogen bonding capabilities due to
the presence of the dien ligand. Nevertheless, the stabilization effects are in line with the trends
of charge and the existence of the central platinum moiety. It should be noted that there are
several factors that affect the overall stability of noncovalent complexes in CID experiments: the
binding energy, the size of the complex (degrees of freedom), internal energy, and charge state of
the ion.

90

AT Duplex with Polynuclear Pt of varying Charge

1.2

1

0.8
Duplex Intensity

free DNA
AH 88 (4+)
AH 59 (6+)

0.6

AH 48 (6+)
AH 44 (6+)
AH 78 (8+)
HOECHST

0.4

0.2

0
10

12

14

16

18

20

22

24

26

28

30

32

34

Collision Voltage

Figure 4.14. Duplex dissociation curve illustrating the increase in
necessary applied collisional energy to achieve strand separation

For drug-DNA complexes an increase in hydrogen bonding character of the drug and the number
of positive charges it carries has a dramatic effect on the overall stability of the complex in the
gas phase. It was shown that when the duplex contains a high number of nucleobase pairs with
low basicity the strand separation profile is generally preferred and the drug remains attached to
one or both strands.24,

25

The above results indicate an increase in overall stability with

increasing size and charge of the platinum compound, but the increase in the vibrational degrees
of freedom should also be considered.
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4.8. Investigation of DNA length
19-mer Oligonucleotide
Additional experiments were conducted on two oligonucleotide duplexes of different lengths
with the goal to see how strand length affects the dissociation pathway. Figure 4.15, shows the
CID

experiments

carried

out

on

the

free

(7-)

19-mer

duplex

GGAAGGACAAACAGGAGAG-3` and (S2)3`- CTTCCTGTTTGTCCTCTCC -5`.

(S1)5`This

duplex contains the central A-T repeat region that is known to enhance the binding of cationic
compounds. As is generally understood, cationic drugs have a strong propensity for the more
negative potential regions associated with ATn repeat units. The collisional energy at which 50%
of the duplex remains (CE50%) was approximately 20 eV. It should be noted that CID in the
QTOF-2 results in predominantly noncovalent dissociation of the duplex into single strands due
to the fast heating conditions. As shown in Figure 4.16, the addition of the +6 trinuclear
compound AH 44 to the duplex increases the CE50% to approximately 27 eV. Much like minor
groove binders, the trinuclear platinum compound remains noncovalently bound to one of the
single strands, showing slight preference to the S1 strand. In addition, the presence of unbound
single strand products indicates loss of the trinuclear platinum compound as a neutral, something
common to intercalators. There does not appear to be any free duplex produced indicating that
the loss of the phosphate clamp motif is a possible secondary fragmentation pathway that occurs
after the noncovalent duplex dissociation. Increasing the overall charge of the platinum drug by
the addition of the two hexane amines on AH 78 creates an opportunity to form two more
phosphate clamp motifs. CID performed on the +8 trinuclear platinum compound AH 78,
increases the CE50% to approximately 30 eV. Similar to the +6 ligand, the +8 compound seems
to show a preference for the S1 strand. As with these compounds, the formation of the phosphate
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clamp binding motif allows the platinum compound to follow the curvature of the phosphate
backbone, thus the propensity of the compound for the S1 strand with the AAA repeat may prove
to warrant further investigations as possible unique binding sites.
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In efforts to determine what effect charge and hydrogen bonding character play on stability, a
smaller dinuclear +4 platinum compound AH 88, was complexed with the 19-mer duplex. As
expected the lower charged dinuclear compound with fewer opportunities for the phosphate
clamp motif, exhibited a lower CE50% of approximately 22 eV. The dissociation profile for the
larger 19-mer oligonucleotide reveals a similar profile when comparing the three platinum
compounds. It should be noted that due to the excessive covalent fragmentation of the phosphate
backbone, the profile plots do not represent a full dissociation of the duplex and therefore the
plot is not 100% dissociated.
Fragmentation Profile 19-mer + Pt Compounds
1.2

1

% Duplex

0.8
19-mer
19-mer + AH 44
19-mer + AH 78
19-mer + AH 88

0.6

0.4

0.2

0
10

14

16

18

20

22

24

26

28

30

32

Collision Energy

Figure 4.16. Duplex dissociation curve illustrating the effect of
charge and size on the duplex gas phase stability
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12-mer Dickerson-Drew Dodecamer
Dissociation of a 12-mer self-complementary duplex (5`- CGCGAATTCGCG -3`) when
complexed with the 6+ AH 44 results in the covalent fragmentation of the duplex with
subsequent phosphate backbone cleavage and base loss. Since this is a self-complementary
sequence, no form of strand sequence preference can be made as the fragments from one strand
would be same as the other. Given the low charge state of this complex (3-), the resultant
covalent fragmentation, may be due to the lack of strand-strand repulsion in addition to the
increase stability provided by the complex.

4.9 Conclusions
The dramatic effects that noncovalent polynuclear platinum compounds exhibit through the
phosphate clamp binding motif is evident in the increased gas phase stabilities of the selected
duplex DNA structures. The trend of increasing electrostatic charge rivals that of increasing the
hydrogen bonding character as seen in the comparison of AH 44 with AH 48. The central
platinum moiety appears to be crucial for the increased stability over similarly charged dinuclear
complexes.

Comparison of the binding mechanism through crystallographic data with the

stability differences, may give an indication that the central platinum region of these types of
phosphate clamp binding motifs is necessary for increased gas phase stability. In addition, the
fragmentation pathway for all compounds appears to be the same regardless of the overall size
and charge. The pathway for dissociation is predictable and comparisons can be drawn with
known minor groove binding compounds. As this binding mechanism encompasses a phosphate
tracking and groove spanning motif, a combination of single strand products with the intact
platinum compound is identified and expected.
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Chapter 5:
Interaction of platinum compounds with model cell membrane structures

5.1 Introduction
Heparan sulfate proteoglycans (HSPGs) are multi-sulfated linear polysaccharides, found on the
cell surface of most human cells and localized in mast cells, play an integral role in a variety of
biological processes. These highly charged polysaccharides, are made up of repeating 1-4 linked
polysulfated disaccharide units comprised of glucosamine and hexuronic acid, with up to three
sulfate moieties per unit. Two structurally similar polysaccharides, heparin and heparan sulfate
(HS) are the most complex members of the glycosaminoglycan (GAG) family, which also
consists of chondrotin sulfate, dermatan sulfate, and keratin sulfate.2 For the work herein we will
only focus on HS. Heparan sulfate is biosynthesized as a proteoglycan and strategically located
on the cell surface and in the extracellular matrix.2 The role of HS has been shown to include a
variety of biological processes ranging from cell adhesion, cell growth regulation, blood
coagulation, binding of cell surface proteins, and tumor metastasis, just to name a few.2 Heparan
sulfate and heparin adopt a stiff helix conformation that positions clusters of sulfate groups at
regularly spaced intervals of approximately 17 Å on either side of the helical axis.3, 4 See Figure
5.1. The helical shape of heparin (Figure 5.1a) shows a close similarity to the helix formed in a
duplex DNA molecule (figure 5.1b).

The DNA crystal structure shows approximately 7-8 Å

spacing between the phosphate clamp interactions between the amines of the AH 78 and the
phosphate oxygen. A quick study of the heparin structure reveals that sulfate oxygen spacing on
a disaccharide unit varies from approximately 5-7 Å. Given the fact that all the noncovalent
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platinum compounds used in this research possess a flexible hexandiamine linker, favorable
electrostatic or hydrogen bond interactions may also occur with the numerous sulfate groups.

A

B

Figure 5.1 PDB database of heparin sulfate (A) and DickersonDrew Dodecamer with AH 78 (B). PDB reference (A) 3IRI (B)
2DYW
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5.2 Heparan sulfate internalization of cationic biomolecules
As mentioned earlier, one of the major requirements for the effectiveness of a platinum
anticancer therapeutic is the successful cellular uptake of the compound. One of the most
remarkable roles of the cell surface HS is the mediation of cellular internalization.2
Research of new drug delivery methods has focused on designing structures that utilize the
endocytic pathway as a means to deliver the bioactive structure into the cell.5 One of the most
successful candidates has been cell penetrating peptides (CPPs), which consist of polycationic
arginine rich oligopeptides, capable of migrating across the biological membrane of cell with a
time range from seconds to minutes.6-8 (For a review, see reference 8.) One of the remarkable
characteristics of CPPs is the ability to assist other biomolecular compounds that may not readily
migrate across the membrane. This requires that the CPPs not be covalently linked to the
biomolecular cargo they are assisting, and also that the binding affinity between the two is
sufficiently high to achieve a stabile transport.9

102

Figure 5.3 Cell surface guanidinium-anionic constituent
interactions.1

For instance, fluorescently labeled CPPs are commonly identified within the cell nucleus which
gives rise to the question: is the fluorescent signal due to the CPP binding strongly with DNA
after the cellular uptake?6 Using in vivo conditions, it has been shown that the binding of CPPs
to DNA involves specific recognition sites and leads to the suggestion that the CPP interacts with
the phosphate backbone of DNA.6
Common to all types of CPPs is the presence of a highly charged cationic region that is essential
for the transport across the membrane.10 This is in stark contrast to the fact that it is commonly
accepted that charged molecules cannot pass through the lipid bilayer by passive diffusion.10
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Two proposed mechanisms for this phenomemon are: (1) the formation of an electrically neutral
complex formed between the cationic CPP and anionic heparan sulfate proteoglycans11, 12, and
(2) the binding of CPPs to the negatively charged lipids thus disrupting the lipid bilayer13 and
more recently, determined to show a strong electrostatic interaction followed by a weak
hydrophobic adsorption/portioning.10
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Figure 5.4 Structural comparison of possible sulfate clamp motif

Comparisons between short peptides with varying arginine and lysine content highlight the
important fact that the overall charge of the CPP is important for uptake.1 A similar charge-touptake correlation has been identified in the polynuclear platinum compounds highlighted in
Chapter 2.14
The association of the positively charged guanidinium group with negatively charged cell surface
structures such as carboxylates, phosphates and sulfates, occurs due to the rigid planar array of
hydrogen bond donors that allow for bidentate bond formation.1 These types of anionic structures
are generally found on the cell membrane as the constituents of phospholipids, fatty acids,
proteins, and heparan sulfate moieties.1 This bidentate bond formation between the two charged
groups provides a stronger interaction than the monodentate and thus, may provide some
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rationalization to why arginines associate and cross the membrane at different levels than the
lysines.1, 15 In addition to the structural differences, it can also be hypothesized that charge is
necessary for successful translocation, but as both polylysines and polyarginines carry a positive
charge, other factors such as the degree of protonation may play a factor.1

As such, the

combination of a bidentate binding structure with a high positive charge in the functional group,
results in the ideal moiety to interact with the phosphates, carboxylates, and sulfates located on
the cell surface.1 Just as the shape and charge are important, so is the effective length of the
oligomer. For polyarginine CPPs, the effective range for cellular translocation was found to be
greater than 6 arginine residues and shorter than 20 residues, with a maximal uptake of
approximately 15 residues.1,

16

The rationale for the decreased translocation of longer

polyarginine structures, is that the increase in length increases the association to a level that is
too high for the effective release of the structure from the membrane.1
As mentioned in Chapter 1, these types of polynuclear platinum compounds have a remarkable
cellular uptake that appears to be based on the charge of the compounds.14 Cellular uptake of
biologically active compounds is a barrier that must be overcome in the development of new
pharmaceutics.17 The cellular surface contains an array of possible anionic binding sites, Figure
5.2 illustrates just the phospholipids and polysaccharide constituents. The interactions of the
guanidinium unit of arginine rich peptides has been examined as a means for cellular
translocation.18 It has been well established that charged compounds do not readily cross the
membrane without some sort of energetic assistance, which may come in the form of pumps or
channels. Arginine rich peptides have been heavily studied because of their ability to translocate
across the plasma membrane of living cells. One recent study predicted that arginine rich
peptides like the TAT peptide float along the anionic phospholipid head group, strongly
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interacting and thus reducing the peptides mobility.19 Binding studies on the affinities of these
cell penetrating peptides indicate a strong electrostatic interaction with anionic species located on
the cell surface, such as lipid head groups, proteins, and proteoglycans, such as heparan
sulfate.17, 20, 21 While studies have shown that the TAT peptides bind to heparan sulfate with a
higher affinity than anionic lipid vesicles, a direct method has yet to be identified.17, 20, 21 As
such, multiple mechanisms are possible and interaction of cell-penetrating peptides results in
aggregation of both anionic lipids and proteoglycans.17, 22, 23

5.3 Mass spectrometry of guanidinium interactions:
Noncovalent interactions are numerous throughout biological systems. The gentle nature of ESIMS ensures that such noncovalent interacting species are transferred from the solution to the gas
phase. Polysulfated oligosaccharide chains are difficult to characterize because of their high
polarity, structural diversity, and sulfate lability.24 Schug and Linder have used ESI-MS to show
that there is a significant difference in interaction strengths between guanidinium and
phosphonate/sulfonates compared to carboxylates.25 In addition, ESI-MS resulted in the
phosphonate/sulfonates displaying a higher propensity to form complexes than the
carboxylates.25 Tandem mass spectrometry (MS/MS) of polysulfated oligosaccharides generally
has four competing fragmentation pathways, (1) cleavage of the glycosidic bonds, (2) SO3 loss
from the isolated precursor ion, (3) charge reduction and equivalent loss of H2SO4, and (4) the
loss of H- from the precursor ion, thus reducing the overall charge.26 It should be noted that
pathway (2) typically dominates in the case of MS/MS analysis of lower charge state sulfated
polysaccharides. The cleavage of the glycosidic bonds are generally preferred when a proton or
another cation are interacting with the glycosidic oxygen.26, 27 For the GAG ions, the overall
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charge state is always lower than the available number of mobile protons, thus increasing the
potential for the protons to be available to destabilize the glycosidic bonds.26

The cases

involving the loss of SO3, generally occur when the available protons are associated with the
sulfate groups, thus rendering the ion with a lower overall charge state.26 However, for these
experiments, the ion of lower charge state is preferred to study the stabilizing effects these new
noncovalent polynuclear complexes induce on the anion GAGs. In addition, the higher charge
state GAG ions result in increased charge-charge repulsion which stress the glycosidic bonds,
making for a competing fragmentation pathway with the loss of sulfate moieties.26 The addition
of ion-pairing molecules, such as ammonium counter ions, displaces sodium adducts, prevents
the loss of sulfate groups, and greatly simplifies the resulting mass spectra.26

5.4 Experimental
Mass spectra were acquired on a Micromass-Waters Qtof-2 mass spectrometer (Milford, MA)
equipped with a custom built microspray source. Samples were introduced by flow injection at
flow rates of 0.5-0.7 µL/min using a syringe pump (Harvard Apparatus). Electrospray source
conditions were kept constant with a source temperature of 120°C and spray voltage of 2.0 kV.
In tandem mass spectrometry (MS/MS) experiments, collisional energy was varied from 10 eV
to 40 eV. Heparan sulfate octasaccharide was purchased from V-Labs (Covington, LA) and
reconstituted in 18 MΩ water to form a 375 µM stock solution. Platinum compounds were
reconstituted in 18 MΩ water to a stock concentration of 500 µM. Samples were mixed at a 1:2
molar ratio in 18 MΩ water with a final concentration of 10mM NH4OAc. Mixtures were
incubated at 37°C for 20 minutes then dialyzed in a custom flow through micro dialysis chamber
at 3 µL/min using 13,000 molecular weight cut off (MWCO) hollow cellulose fibers from
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SpectraPor, (Rancho Dominguez, CA) and recollected. DPPS and DPPA phospholipids were
purchased from Avanti Inc, (Alabaster, AL). Samples were mixed in chloride free pipes buffer
(pH = 7.4) at a molar ratio of 1:2. Following incubation at 37 °C suspensions were extracted
using chloroform. The extract was then lyophilized to dryness and reconstituted in ESI solution.

5.5 Results and discussion
In this study, gas-phase interactions between heparan sulfate (HS) octasaccharides and
noncovalent polynuclear platinum compounds of varying size (dinuclear and trinuclear) and
charge (4+ to 8+) were investigated using ESI-MS.

This is the first such experiment

investigating the interaction of a noncovalent platinum compound with a sulfated polysaccharide.
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The HS octasaccharide was chosen to serves as a model system for the HS found on the surface
of cells and to represent a possible means of cellular internalization of these types of platinum
compounds. Figure 5.5 shows the free 3- charge state of a HS octasaccharide, designated (A)
799 m/z, at 10V of collisional energy. Under these ESI-MS/MS conditions the sulfates are
extremely labile, as expected during the negative mode acquisition. The addition of ammonium
acetate to the ESI solution results in ammonium salt NH4+ binding to the sulfates which, during
the ESI desolvation process release as ammonium NH3. The resultant protonated HSO3 is less
stable than NaSO3 and easily fragments from the oligosaccahride.
The 10V of collision energy, which is usually a starting point for all MS/MS experiments in this
laboratory, as it provides efficient ion cooling and aids in the transfer of the ion packets, results
in the sequential loss of sulfates. It should be noted that the low charge state (3-) used for these
experiments typically favors the loss of sulfates from the glycosidic backbone. Higher charge
states for these types of complexes have been difficult to obtain. This is most likely due to the
energetics applied to the ions associated with the QTOF-2. This has been illustrated by Naggar
et. al where they point out that the lack of higher charge states in the ESI-MS of GAG molecules
may be due to the high energetic penalty of desolvation on an orthogonal time of flight
instrument.26 As illustrated in Figure 5.5, it is evident that HS octasaccharide loses up to six
sulfates upon “gentle” collision settings, again, owing to the labile nature of the sulfates in the
gas-phase. As the collision energy is increased from 10 to 20V, the extent of the sulfate loss
increases to eight total sulfates. Of the 12 total sulfates associated with this octasaccharide, 8 are
of the HSO3 structure and 4 are found as H2SO4 structures. (see Figure 5.2) The collision voltage
of 30V results in a loss of a total 9 sulfates without any detectible glycosidic bond cleavages, or
change in the overall charge state. Figure 5.6. The identification of the preferred dissociation
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pathway for this HS octamer being the sequential loss of sulfate rather than cleavage of the
glycosidic bonds, makes this system amenable for studying the noncovalent interactions of the
platinum compounds with sulfates.

J
61.6

100

FFree
Free
ree Octasaccaride
@@
30V30V
Octasaccharide

%

I

K

H

0
200

300

400

500

600

700

800

900

1000

1100

1200

1300

1400

1500

1600

1700

1800

1900

m/z

Figure 5.6 (A) Free Octasaccharide, (B) loss of (SO3), (C) loss of (SO3)2, (D)
loss of (SO3)3, (E) loss of (SO3)4, (F) loss of (SO3)5, (G) loss of (SO3)6, (H) loss
of (SO3)7 (I) loss of (SO3)8, (J) loss of (SO3)9, (K) loss of (SO3)10,H2SO4

ESI-MS/MS studies of Heparan Sulfate Octasaccharide with Noncovalent Polynuclear Platinum
Compounds
To investigate the fragmentation pathway for the complexation of HS and noncovalent platinum
compounds (AH 88, AH 44, and AH 78), ESI-MS/MS studies were conducted see Figure 3.2.
The [HS-Pt]3- ion was fragmented at varying collision energies 10, 20, and 30 V. Figure 5.7
shows the fragmentation profile at 10V of collisional energy. The fragments observed are
characteristic of the same sulfate loss pathway seen in the free octasaccharide.
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Figure 5.7 (A) AH88- Octasaccharide, (B) loss of (SO3), (C) loss of (SO3)2,
(D) loss of (SO3)3,

However, it is clear that the addition of the 4+ charged dinuclear platinum compound AH 88,
results in an increased stabilization of the sulfate moieties.Figures 5.8 shows the resultant
ltant
fragmentation products from 30 V of collisional energy, respectively. The dominant peaks
correspond to the loss of five and six sulfates, 832m/z and 805 m/z, shown as (F) and (G) in
Figure 5.8, respectively. Careful identification of the spectra shows that as the collision energy
is increased, there is a new series of peaks that begin to appear, corresponding to the loss of a H+
and the attachment of a Na+ ion, 837 m/z and 810 m/z. The binding between HS and AH 88 is
strong, as there is not direct evidence of free HS in the ESI-MS/MS spectra. The subsequent loss
of up to six sulfate moieties does not deter the interaction between the two complexes.
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Figure 5.9 illustrates the ESI-MS/MS spectra of the 3- charge state of the noncovalent trinuclear
compound AH 44 with HS, (peak A), at 10 V of collision energy.
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Figure 5.10 shows the isolation and fragmentation of the 3- charge state of the 8+ AH 78 with
HS, (peak A). The loss of sulfate from the intact structure still occurs, but is only representative
of approximately 10% of the relative abundance of the intact species. Increasing the voltage
from 20 to 30 V, as depicted in Figure 5.10, yields a maximum of three sulfate moieties lost
during the MS/MS.
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Interaction of Noncovalent Polynuclear Compounds with Phospholipids
In efforts to look at the possible interactions of these compounds with anionic cell surface
structures, namely phospholipids, an ESI-MS study was done.

Previous work has been

accomplished using ESI-MS and NMR as a means to study these polynuclear platinum
compounds interacting with lipid structures.30 In those studies, the covalent platinum compound
BBR 3464 was found to exhibit a slight electrostatic association with negative phospholipids
head groups. Additionally, a comparison of the binding affinity showed that the DPPA (mw 647
Da) had a slightly higher binding affinity than DPPS (mw 734 Da), which was attributed to the
smaller phosphate head group of DPPA having more electronic density.30 For the work done
here, a liposome-Pt extract was reconstituted in ESI spray solution consisting of 80% MEOH,
15% CHCl3, and 5% 10mM ammonium acetate.
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Figure 5.11 shows the resultant positive ESI-MS spectra of the liposome-Pt extract.

The

dominant peak in the spectra corresponds to the 3+ ion and electrostatic interaction of three
intact DPPA lipids with one AH 44 trinuclear platinum compound at 966 m/z. Additionally, the
presence of peaks with four DDPA lipids electrostatically bound to AH 44 is also detected at
1182 and 1773 m/z respectively.
Figure 5.12 shows the ESI-MS spectra of the phospholopid DPPS with AH 44.

The

phospholipid DPPS contains a phosphatidyl-serine head group that presents multiple sites for
formation of the “clamp” type binding motif. The notable peaks are 1053 m/z, 1298 m/z, and the
1544 m/z, these correspond to the electrostatic association of three, four, and five intact DPPS
lipids, respectively. Also, careful examination of the peak located at 1023 m/z reveals a loss of
87 Da, which would correspond to the loss of one serine head group moiety from the lipid
structure. Additionally, this is also evident for the 4DDPS gas phase structure, as noted by the
peak at 1269 m/z.
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While only a marginal conclusion can be drawn, this may give some indication that the preferred
binding site is the phosphate portion of the lipid headgroup. It is undetermined weather the
product of the cleavage is the result of the electrospray process or some other event prior to the
electrostatic association with the AH 44.

The ESI-MS of the DPPA and DPPS with the trinuclear 8+ compound AH 78 reveal a similar
type binding profile. Figure 5.13 shows the peaks obtained from the samples extracted from the
mixture of DPPA with AH 78. The interaction appears to be more favorable than that observed
for the AH 44. As the case of AH 44, a distribution of electrostatic associations range from 3-6
DPPA intact lipid structures. The most intense peaks correspond to the distribution of three,
four, and five DPPA moieties.
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Figure 5.13Positive ESI-MS of DPPA with AH 78. Increasing the
overall charge of the platinum compound results in a larger number of
electrostatic interactions ranging from 3-6 DPPA lipids.
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The binding profile of AH 78 with DPPS is less complicated than that of AH 44 for reasons
undetermined. Examination of Figure 5.14 reveals the noncovalent association of up to six
DPPS lipids per AH 78 compound.

However, unlike before, there appears little to no

fragmentation of the phosphatidyl-serine head group. The major species present in the spectra
corresponds to the 3+ charge state of three DPPS lipids with one AH 78 at 1119 m/z. An
unresolved peak shift of 57 Da is seen for all species present in solution. At this time, no attempt
has been made to provide an explanation and further purification of the sample before ESI-MS
may be necessary. The ion intensity for the four and five DPPS-Pt structures appears equivalent
at 1365 and 1610 m/z, respectfully.
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Figure 5.14 ESI-MS of DPPS with AH 78 showing up to six DPPS
intact lipid structures binding through electrostatic associations.
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No evidence for any higher number structures exists in the spectra. This may be the result of the
square planar geometry of the Pt centers and the fact that two “phosphate clamps” are able to
form on either side of the platinum compound. A proposed structure of this binding arrangement
is seen in Figure 5.15. Based on the phosphate clamp motif with DNA, as shown by crystal
structure, one platinum center is cable of forming the clamping motif with multiple anionic
structures. Such is the case presented here with all available sites occupied with phosophate
clamp motifs.

Figure 5.15 Proposed binding scheme of up to six DPPA lipids with AH 78
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5.6 Conclusions
The results obtained from the ESI-MS/MS of the HS octasaccharide electrostatically bound with
a noncovalent polynuclear platinum compound suggest the main dissociation pathway is
cleavage of the labile sulfate moieties. While the quantitative measure of the binding energies
cannot be accessed, the strength of the interaction between the HS and “sulfate” clamps is
remarkable. It should be mentioned that the strength of electrostatic interactions is actually
strengthened in the gas phase compared to solution phase.28 1&6 This added association strength
comes from the dielectric constant of the solvents used in the experiment as they tend to weaken
the electrostatic interactions.28 At the higher voltages used, 30V, there are some fragmentations
of the HS polysaccharide structure.

However, these are negligible when compared to the

intensity of the ions from sulfate loss and is less than 3% of the base peak intensity. Increasing
the size and charge of the noncovalent platinum compound results in an increased overall
stability of the complex and fewer sulfate moieties lost during the MS/MS experiment. As
mentioned earlier, the higher the charge state or more deprotonated a GAG is, the higher the
propensity is for glycosidic bond cleavage.

In the case with the noncovalent polynuclear

compounds, the ability to form a “sulfate clamp” binding motif limits the available number of
sulfates that are able to become deprotonated and therefore the major fragmentation pathway is
loss of sulfate moieties. It has been observed that for gas-phase dissociations, the lability of
sulfate groups tend to follow the order of SO3H > SO3 > SO3Na.29 Therefore as the number of
sodium adducts increases that amount of sulfate loss decreases. This is the similar trend for the
noncovalent platinum complexes. As such, this example of increased stability serves as a
method for verifying the complexation with sulfate moieties and not elsewhere on the glycosidic
backbone. To reiterate, the perceived increase in stability and therefore lack of sulfate loss

119
exhibited by these complexations follows the existing methodology that cations binding to the
anionic sulfate help stabilize the structure from sulfate loss. This helps strengthen the argument
that these noncovalent platinum complexes are able to bind sulfate moieties in a similar fashion
as the phosphate clamp binding motif. Analogous to the studies of the gas-phase stabilities with
utilizing the phosphate clamp binding motif on DNA, these results with sulfate indicate a very
strong interaction. The MS/MS studies reveal a preferred dissociation pathway of sulfate loss
with no dissociation of the noncovalent platinum compound from the heparan sulfate
polysaccharide.
In addition, the ESI-MS results of the DPPS and DPPA with AH 44 and AH 78, help illustrate a
possible phospholipid association. Based on the observed peaks in the ESI-MS experiments with
up to six phospholipids bound to one platinum compound, it is conceivable to think that the
structure represented in Figure 5.14 could represent the movement of a noncovalent platinum
compound through the lipid bilayer as a means of cellular uptake. As charged compounds do not
readily permeate the membrane, the neutralization via the phosphate head groups may assist in
the migration. Additional experiments with different lipid head group structures needs to be
addressed as a way to identify the binding affinity for model cell surface structures.

120
5.7 References
1.

Wender, P. A.; Galliher, W. C.; Goun, E. A.; Jones, L. R.; Pillow, T. H., The design of

guanidinium-rich transporters and their internalization mechanisms. Advanced Drug Delivery
Reviews 2008, 60, (4-5), 452-472.
2.

Rabenstein, D. L., Heparin and heparan sulfate: structure and function. Nat Prod Rep

2002, 19, (3), 312-31.
3.

Vlodavsky, I.; Ilan, N.; Nadir, Y.; Brenner, B.; Katz, B. Z.; Naggi, A.; Torri, G.; Casu,

B.; Sasisekharan, R., Heparanase, heparin and the coagulation system in cancer progression.
Thromb Res 2007, 120 Suppl 2, S112-20.
4.

Mulloy, B.; Forster, M. J.; Jones, C.; Davies, D. B., N.M.R. and molecular-modelling

studies of the solution conformation of heparin. Biochem. J. 1993, 293, (3), 849-858.
5.

Jones, A. T., Gateways and tools for drug delivery: Endocytic pathways and the cellular

dynamics of cell penetrating peptides. International Journal of Pharmaceutics 2008, 354, (1-2),
34-38.
6.

Ziegler, A.; Seelig, J., High Affinity of the Cell-Penetrating Peptide HIV-1 Tat-PTD for

DNA. Biochemistry 2007, 46, (27), 8138-8145.
7.

Schwarze, S. R.; Hruska, K. A.; Dowdy, S. F., Protein transduction: unrestricted delivery

into all cells? Trends Cell Biol 2000, 10, (7), 290-5.
8.

Lindgren, M.; Hallbrink, M.; Prochiantz, A.; Langel, U., Cell-penetrating peptides.

Trends Pharmacol Sci 2000, 21, (3), 99-103.
9.

Choosakoonkriang, S.; Lobo, B. A.; Koe, G. S.; Koe, J. G.; Middaugh, C. R., Biophysical

characterization of PEI/DNA complexes. J Pharm Sci 2003, 92, (8), 1710-22.

121
10.

Ziegler, A.; LiBlatter, X.; Seelig, A.; Seelig, J., Protein Transduction Domains of HIV-1

and SIV TAT Interact with Charged Lipid Vesicles. Binding Mechanism and Thermodynamic
Analysis. Biochemistry 2003, 42, (30), 9185-9194.
11.

Frankel, A. D.; Pabo, C. O., Cellular uptake of the tat protein from human

immunodeficiency virus. Cell 1988, 55, (6), 1189-93.
12.

Tyagi, M.; Rusnati, M.; Presta, M.; Giacca, M., Internalization of HIV-1 tat requires cell

surface heparan sulfate proteoglycans. J Biol Chem 2001, 276, (5), 3254-61.
13.

Prochiantz, A., Messenger proteins: homeoproteins, TAT and others. Curr Opin Cell Biol

2000, 12, (4), 400-6.
14.

Harris, A. L.; Yang, X.; Hegmans, A.; Povirk, L.; Ryan, J. J.; Kelland, L.; Farrell, N. P.,

Synthesis, Characterization, and Cytotoxicity of a Novel Highly Charged Trinuclear Platinum
Compound. Enhancement of Cellular Uptake with Charge. Inorg. Chem. 2005, 44, (26), 95989600.
15.

Mitchell, D. J.; Kim, D. T.; Steinman, L.; Fathman, C. G.; Rothbard, J. B., Polyarginine

enters cells more efficiently than other polycationic homopolymers. J Pept Res 2000, 56, (5),
318-25.
16.

Wender, P. A.; Mitchell, D. J.; Pattabiraman, K.; Pelkey, E. T.; Steinman, L.; Rothbard,

J. B., The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake:
peptoid molecular transporters. Proc Natl Acad Sci U S A 2000, 97, (24), 13003-8.
17.

Schmidt, N.; Mishra, A.; Lai, G. H.; Wong, G. C., Arginine-rich cell-penetrating

peptides. FEBS Lett 2009.

122
18.

Tang, M.; Waring, A. J.; Hong, M., Phosphate-Mediated Arginine Insertion into Lipid

Membranes and Pore Formation by a Cationic Membrane Peptide from Solid-State NMR.
Journal of the American Chemical Society 2007, 129, (37), 11438-11446.
19.

Ciobanasu, C.; Harms, E.; Tunnemann, G.; Cardoso, M. C.; Kubitscheck, U., Cell-

penetrating HIV1 TAT peptides float on model lipid bilayers. Biochemistry 2009, 48, (22), 472837.
20.

Ziegler, A.; Blatter, X. L.; Seelig, A.; Seelig, J., Protein transduction domains of HIV-1

and SIV TAT interact with charged lipid vesicles. Binding mechanism and thermodynamic
analysis. Biochemistry 2003, 42, (30), 9185-94.
21.

Goncalves, E.; Kitas, E.; Seelig, J., Binding of oligoarginine to membrane lipids and

heparan sulfate: structural and thermodynamic characterization of a cell-penetrating peptide.
Biochemistry 2005, 44, (7), 2692-702.
22.

Tiriveedhi, V.; Butko, P., A fluorescence spectroscopy study on the interactions of the

TAT-PTD peptide with model lipid membranes. Biochemistry 2007, 46, (12), 3888-95.
23.

Ziegler, A.; Seelig, J., Binding and clustering of glycosaminoglycans: a common property

of mono- and multivalent cell-penetrating compounds. Biophys J 2008, 94, (6), 2142-9.
24.

Chai, W. G.; Luo, J. L.; Lim, C. K.; Lawson, A. M., Characterization of heparin

oligosaccharide mixtures as ammonium salts using electrospray mass spectrometry. Analytical
Chemistry 1998, 70, (10), 2060-2066.
25.

Schug, K. A.; Lindner, W., Noncovalent binding between guanidinium and anionic

groups: focus on biological- and synthetic-based arginine/guanidinium interactions with
phosph[on]ate and sulf[on]ate residues. Chem Rev 2005, 105, (1), 67-114.

123
26.

Naggar, E. F.; Costello, C. E.; Zaia, J., Competing fragmentation processes in tandem

mass spectra of heparin-like glycosaminoglycans. J Am Soc Mass Spectrom 2004, 15, (11),
1534-44.
27.

Hofmeister, G. E.; Zhou, Z.; Leary, J. A., Linkage position determination in lithium-

cationized disaccharides: tandem mass spectrometry and semiempirical calculations. Journal of
the American Chemical Society 1991, 113, (16), 5964-5970.
28.

Jackson, S. N.; Wang, H. Y.; Woods, A. S., Study of the fragmentation patterns of the

phosphate-arginine noncovalent bond. J Proteome Res 2005, 4, (6), 2360-3.
29.

Yagami, T.; Kitagawa, K.; Aida, C.; Fujiwara, H.; Futaki, S., Stabilization of a tyrosine

O-sulfate residue by a cationic functional group: formation of a conjugate acid-base pair. J Pept
Res 2000, 56, (4), 239-49.
30.

Liu, Q.; Qu, Y.; Van Antwerpen, R.; Farrell, N., Mechanism of the Membrane Interaction

of Polynuclear Platinum Anticancer Agents. Implications for Cellular Uptake. Biochemistry
2006, 45, 4248-4256.

124

Chapter 6
Solution Composition and Thermal Denaturation for the Production of
Single-Stranded PCR Amplicons: Piperidine-Induced Destabilization of
the DNA Duplex?
John B. Mangrum, Jason W. Flora, and David C. Muddiman
Department of Chemistry, Virginia Commonwealth University, Richmond, Virginia, USA
Journal of the American Society for Mass Spectrometry, 13(3); 2002, 232-240

6.1 Introduction
The precise determination of DNA sequence variations requires methodologies that are
sensitive, accurate, and have high throughput efficiency. Electrospray ionization1Fourier
transform ion cyclotron resonance mass spectrometry2 (ESI-FTICR-MS) has proven to be
an ideal method for genotyping length polymorphisms, such as, short tandem repeats
(STRs).3, 4 In determining sequence variations for use as genetic markers, these STRs are
invaluable as they are highly polymorphic5, 6, have an occurrence approximately every
10-20 kilo bases (kb) in the genome7-9, and can be easily isolated using polymerase chain
reaction (PCR) methods7, 8, 10 ESI-MS typically results in the observation of duplex PCR
amplicons.3, 4, 11-20, as the Watson-Crick base pairing21 is retained in the gas phase.
ESI when paired with FTICR has the advantage of being able to detect large molecules22
with the measurement of large PCR amplicons up to 500 bp in length.16 In addition, the
ESI-FTICR method has allowed a single acquisition mass spectra to be collected from
5nM solutions of PCR amplicons.20 The fitting of a modified dual electrospray source23
has allowed for the mass accuracies approaching the theoretical limit ±10 ppm for large
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biomolecules (>10 kDa).24 However, the challenge to acquire mass accuracies high
enough to accurately genotype length polymorphisms derived from complex STRs,
which contain multiple repeat units, base insertions, and deletions, is still hampered.25
This difficulty in obtaining accurate mass measurements of duplex PCR amplicons
occurs because a base substitution, such as an A→T transversion, cannot be resolved by
mass spectrometry because the complementary strand would also have a T→A
transversion resulting in a zero mass difference. Therefore, it is necessary to be able to
routinely generate single-stranded (ss) PCR amplicons for accurate characterization of
base substitutions within STRs.3, 15
A survey through the literature reveals several strategies for the routine production of
single stranded PCR products using mass spectrometry such as, nozzle skimmer
dissociation

26

, biotin-streptavidin chemistry27-33, and the use of a DNA repair enzyme,

lambda exonuclease.3, 15 Gabelica et al. have used nozzle skimmer dissociation on ad 16mer oligonucleotide with a G-C content approaching 75% to achieve complete
dissociation with no sign of covalent backbone cleavage.26 Research from this group on
the nozzle skimmer dissociation of a 20-mer oligonucleotide with a G-C content of
approximately 70% yield single stranded species, but a majority of the duplex structure
remained and a significant amount of backbone cleavage was evident. The use of biotinstreptavidin magnetic beads has been shown to be effective, but sufficient sample loss has
been shown to occur when trying to remove the strands form the bead surfaces.3, 15 The
use of lambda exonuclease to selectively digest the 5' phosphorylated strand of the duplex
structure leaving only the complementary strand remaining has been shown to be
effective3, 15, but this method requires an additional enzymatic digestion step and in the
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event of incomplete phosphorylation of the PCR primers, the amplicons are resistant to
degradation.3, 15
Efforts to generate single stranded amplicons prior to entering the mass spectrometer
have been shown by Williams and co-workers using thermal denaturation with the use of
a resistively heated wire34 This method is advantageous because it eliminates the
probability of sample contamination since sample handling is reduced. This research
focuses on the manipulation of solution compositions and thermal denaturation during the
ESI process to control the stability of DNA duplexes in efforts to routinely generate
single stranded species.

The experimental conditions allow for the tailoring of the

solutions to promote either single-stranded or double-stranded on the fly prior to the
entrance into the mass spectrometer.

6.2 Experimental

Materials and Sample Preparation
Synthetic complementary 20-mer oligonucleotides 5'-CAGCGTGCGCCATCCTTCCC-3'
and 5'-GGGAAGGATGGCGCACGCTG-3' were purchased from Midland Certified
Reagent Company (Midland, TX). The oligonucleotides were desalted prior to ESI-MS
using a microdialysis setup utilizing a hollow microdialysis membrane with 18,000
MWCO.17, 35 The complementary 20-mers were annealed at a 1:1 molar ratio at 90°C for
2 minutes in their ESI solutions (vide infra) and slowly cooled back to room temperature.
The final concentration of duplex was 4µM when prepared in ESI solutions. The 20-mer
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duplex (MW = 12237.9) has an estimated melting temperature (Tm) of 71.6°C, which was
calculated using the following equation36:

Tm = 22 + 1.46(In) where In = 2 x (#GC base pairs) + (#AT base pairs)

(Eq. 1)

The Tm is defined as the temperature at which one half of the duplex structure is in a
denatured state. All other reagents were purchased from Sigma-Aldrich (St. Louis, MO);
and used without further purification.

Mass Spectrometry
All spectra were obtained using a modified IonSpec Corporation (Irvine, CA) FTICR
mass spectrometer with a 4.7 tesla superconducting magnet (Cryomagnetics, Inc. Oak
Ridge TN). The ESI source (Analytica of Brandford Inc, Branford, CT) was modified
with a heated metal capillary37 applying a constant temperature (allowing for routine
detection of noncovalent complexes with exception) for all experiments, and microelectrospray emitter tips. The tips were hand pulled from a fused-silica capillary 50µm to
10µm i.d.38 All samples were directly infused using a Harvard syringe pump, (South
Natick, MA) at an infusion rate of 0.4 µL/min. All spectra were single acquisitions using
512 k of data for 20-mer oligonucleotides and 32 k of data for 82-bp HUMTHO1 PCR
amplicons, acquired at 500 kHz ADC rate. Acquistions involved two 1-sec hexapole
accumulations followd by gated trapping.39 The unapodized data were zero filled two
times and Fourier transformed prior to spectral analysis. Figure 1. shows a schematic of
the heated transfer line used for thermal denaturation experiments. The transfer line was
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constructed using as 24V DC power supply (Springboro, OH) to apply a DC voltage to
the monochrome wire coiled around high temperature insulation. Real time temperature
measurements were acquired using a thermocouple attached between the transfer line and
insulation. Temperatures were displayed on an Omega CN9000A readout (Stamford,
CT).

Restively heated wire

metal capillary
Insulation
Emitter tip

I
37.3
DC Power Supply

Thermocouple

Figure 6.1: Schematic of ESI source with resistively heated transfer
line.
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6.3 Results and Discussion
The ESI-FTICR mass spectrum shown in Figure 6.2a is a double-stranded 20-mer
oligonucleoide with a Tm = 71.6 ºC using the current electrospray solution of 60%
acetonitrile, 20% isopropyl alchohol, 20% acqueous phase with at final concentration of 2
mM ammonium acetate, and 20 mM piperdine and imidazole.3, 4 3, 15-20
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Figure 6.2: ESI-FTICR mass spectra of 20-mer
oligonucleotides using original ESI solution consisting
of 60% acetonirile, 20% isopropyl alcohol, 20% 10
mM ammonium acetate with final concentration of 20
mM Piperidine and Imidazole. A) dsDNA is observed
at ambient temperature (28° C). B) Only ssDNA is
observed when temperature of the heated metal
transfer line is significantly above its Tm (88.4° C).
All charge states and coding (C) and noncoding (NC)
strands are labeled.
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The spectrum in Figure 6.2b shows the result of using a resistively heated transfer line
providing thermal denaturation of the 20-mer duplex as it was introduced into the
entrance of the mass spectrometer.

The elevated temperature that was required to

destabilize the large number of hydrogen bonds between the nucleobases resulted in a
highly unstable electrospray, which caused ion intensity issues and lack or reproducible
results. In efforts to circumvent the instability and low signal to noise during the thermal
denaturation, modifications to the electrospray solutions were examined and increases to
the aqueous content were made. As the proportion of aqueous content of the electrospray
solutions was increased the dsDNA became denatured and single stranded DNA ssDNA
was detected. Figure 6.3 shows the ESI-FTICR mass spectra of the 20-mer dsDNA at
ambient temperature with various aqueous content percentages as a plot of relative ion
intensity of the single stranded species Iss, divided by the total ion intensity, Iss + Ids,
versus the percentage of aqueous content. The ESI solutions with 25% of aqueous
content contained all duplex structure. As the percentage is increase to 40%, the spectra
now contains the 20-mer DNA in both the duplex and single stranded forms.

As the

content surpassed 50-60%, only single stranded DNA remained in the spectra.
It should be noted that the signal to noise ratio shown in Figures 6.2b and 6.3 appears
slightly compromised by the higher than normal aqueous content used in the solutions.
This may be attributed to the following scenarios: (1) the total ion intensity is distributed
among four species (C4-,NC4-,C3-, and NC3-) at the higher 55% aqueous content rather
than just two species (ds6-, and ds5-) at the lower content, 25%; (2) increasing the aqueous
content results in a higher surface tension of the dropets, yet the heated metal capillary
was maintained at a constant temperature, so incomplete desolvation and lower ion
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production may be related; (3) The FTICR signals scales linearly with charge, so for
lower charge states (i.e. single strands) they induce less of an image current than the
duplex species. Also of note, the average charge state for the duplex species increases
with the increase in aqueous content, (Figure 6.3). This may be due to: (1) the higher
aqueous content droplets accommodate a higher charge density, and therefore impart
more charge onto the oligonucleotide structure, and (2) the apparent pH of the solution
increases slightly with increasing the aqueous content. The increase in pH decreases the
relative proportion of protonated piperdine which is known to reduce charge states when
in the protonated form.40
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The single stranded products in Figure 6.3 show no sign of backbone fragmentation and
represent the individual intact single stranded species. This is consistent with the work
by Gabelica et al. in which they used a higher proportion of aqueous content for the
nozzle skimmer dissociation of the 16-mer duplexes.26

The nozzle skimmer

dissociations from this research was done using an ESI solution that was conducive for
duplex stabilization (ie, 20% aqueous) and therefore the higher amounts of backbone
fragmentation resulted.
Based on the positive results with the 20-mer model system, attention was directed to an
82-bp PCR amplicon that was electrosprayed from solutions with 50-70% aqueous
content. The higher percentatages were chosen based on the higher number of hydrogen
bond associated with the greater number or base pairs. The estimated Tm for the PCR
amplicon was determined using the following equation36:

Tm = 81.5 + [16.6(log[X+])] + [0.41(%GC)] – [500 / # of base pairs]

(Eq.2)

This equation is only valid for monovalent cation concentrations, represented by [X+], in
the range of 0.01-0.4M and the DNA duplex of interests must contain a GC percentage
between 30-75%.36 The sodium concentration was assumed to be zero since all samples
were thoroughly dialyzed to remove salt adduction. However, the solutions also contain
ammonium ions and protonated piperidine. The Tm was calculated using protonated
piperidine concentrations determined by α-values for a given pH. Figure 6.4a illustrates
the ESI-FTICR mass spectrum of a stable DNA duplex at 50% aqueous ESI solution (pH
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= 11.1; Tm = 58.5 °C). Figure 6.4b shows the same 82-bp PCR amplicon now at 60%
aqueous content, which shows only a marginal amount of single stranded product( pH =
11.2; Tm = 57.6 °C). Figure 6.4c shows a completely denatured 82-bp PCR product at
70% aqueous phase( pH = 11.3; Tm = 56.9 °C). The increase in aqueous character of the
solution increased the pH also, which decreased the amount of protonated piperidine and
therefore decreased the ionic strength of the solution. However, the range of ionic
strengths is very narrow, and the melting temperatures only changed by 1.6 °C which
suggest that additional factors play a role in the DNA duplex stability such as the degree
of hydration and the hydrogen bonding capability of neutral piperidine.
Experiments were then done to thermally control the state of the species (ssDNA or
dsDNA) observed in the spectrum. A resistive heating of the transfer line was conducted
using 60% aqueous solution (pH = 11.2; Tm = 57.6 °C) as it appears to be right on the
threshold of dsDNA stability, shown in Figure 6.4b. The 82-bp PCR product in 60%
aqueous solution with increasing capillary temperature is shown in Figure 6.5. This
method of analysis allows for the simultaneous detection of both ssDNA and dsDNA in
the same ESI experimental run. Figure 6.5 shows a plot of the relative ion intensity
versus the temperature of the heated transfer line measured at the insulating jacket. At a
temperature of 28 °C, the 82-bp product is detected as mainly dsDNA.

As the

temperature of the surrounding heating jacket is increased to 42 °C, the PCR product is
observed as both dsDNA and ssDNA states. Increasing the temperature of the capillary
to 53 °C, results in the production of predominantly ssDNA species. The observation of
dsDNA destabilization at 53 °C is below our calculated Tm 57.6°C, which is consistent
with the observations in Figures 6.3 and 6.4, that higher aqueous phase in the ESI
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solution decreases Tm. It was found that an increase in aqueous content increases the
apparent pH of each solution. This indicated that the pH of ESI solution might play a
critical role in the DNA duplex stability. In the ESI solution is piperidine, a strong base
(pKa = 11.1), which raises the pH of the solutions as well as reduces the alkali metal
adduction40 Based on aqueous phase α-plot for piperidine, at pH values below its pKa,
piperidine is in its protonated form in the solution.

At pH values above the pKa,

piperidine resides primarily in a neutral state. In accord with the α-plot, α0 = 0.61 for the
protonated form and α1 = 0.39 for the neutral piperidine in the 20 % aqueous solution,
which has an apparent pH = 10.9. The corresponding values for the 55% aqueous
solution with an apparent pH of 11.3, is α0 = 0.43 for the protonated form and α1 = 0.57.
For the 20-mer oligonucleotide, these two aqueous percentages and their corresponding
α-values illustrate that the percentage of protontated and neutral piperdine in solution
seem to play a crucial role in the state of the DNA.
Figure 6.6 shows an ESI-FTICR mass spectra of the 20-mer oligonucleotide from
solutions without imidazole. This was chosen to simplify the ESI mixtures. Figure 6.6a
shows a mass spectrum of the 20-mer in 20% aqueous solution in which the dsDNA is
observed as expected for this pH. Figure 6.6b shows the same 20-mer in 55% aqueous
solution, which induces the production of ssDNA.
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137
Figure 6.6c shows that by lowering the pH of the 55% solution with acetic acid to less
than 11.0 the ssDNA is resorts back to the dsDNA conformation. When the apparent pH
is above the pKa of piperidine, the DNA is destabilized and produces single stranded
products. As the apparent pH is reduced below the pKa of piperidine, the DNA in
solution is of the duplex form. It should be noted that there is a small decrease in the
average charge state of the duplexes shown in Figure 6.6a and 6.6c, to roughly 5.6 and
5.1, respectively. This decrease in average charge state is due to the approximately 6%
increase in the protonated form of piperidine, which is known to reduce charge states.40
Scheme 1, illustrates the proposed mechanism for piperidine interaction based upon the
experimental data and the α-plot values for piperidine. At pH values below the pKa, the
excess of protonated piperidine acts like a cation and electrostatically binds to the
phosphate backbone thus neutralizing the strand-strand repulsion of the negatively
charged backbone. This creates a similar structure such as peptide nucleic acids (PNAs)
where there is no negative-negative repulsions and increased duplex stability exists.41 At
pH values that are above the pKa of piperidine, the excess of neutral piperidine can
hydrogen bond with the nucleabases of the double helix and thus act in an analogous
fashion as the known denaturant formamide.42
To further investigate this possible mechanism, a study of melting temperature of the 20mer duplex in two different ESI solutions with different pH values was undertaken.
Figure 6.7 is a plot of the relative intensity of the ssDNA versus the temperature of the
resistively heated transfer line at 30% aqueous solution. The pH values are 10.9 and 10.7
respectivley, adjusted with acetic acid. When the 10.9 solution is electrosprayed at room
temperature (28 °C), the mass spectrum shows the dsDNA conformation.
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Heating the transfer line to 58 °C, results in almost complete denaturation of the 20-mer.
However, for the ESI solution with the lower pH value, 10.7, increased duplex stability is
observed. Temperatures of over 100 °C were necessary to achieve dissociation of the
dsDNA. Analogous to PNA-PNA duplex stability43, the oligonucletide in the lower pH
solution and thus more protonated piperdine, stabilizes the anionic phosphate backbone
of the double helix. The result is an increase in the melting temperature that is roughly
twice the value of the higher pH solution 20-mer. The decrease in pH from 10.9 to 10.7
is reflected in the charge-states observed for the dsDNA at ambient temperatures. When
the concentration of protonated piperidine increase by 9%, the average charge state of the
dsDNA decreases.
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6.4 Conclusions
The ESI solutions are relatively complex and numerous factors play a role in the DNA
stability( e.g., ionic strength which is pH dependent, aqueous content, and temperature).
A higher detailed study of these factors is warranted to fully understand the role in the
processes observed. Conductivity measurements were done, but results were inconclusive
and also warrant further investigations. Never the less, single stranded moieties can be
routinely generated from double stranded PCR products using a combination of aqueous
solution modifications and restively heated electrospray sources.
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Appendix A
Investigation into Mulinuclear Ruthenium Compund Binding with DNA
Work used in the publication of:
Mendoza-Ferri, M. G.; Hartinger, C. G.; Mendoza, M. A.; Groessl, M.; Egger, A. E.;
Eichinger, R. E.; Mangrum, J. B.; Farrell, N. P.; Maruszak, M.; Bednarski, P. J.; Klein,
F.; Jakupec, M. A.; Nazarov, A. A.; Severin, K.; Keppler, B. K., Transferring the
Concept of Multinuclearity to Ruthenium Complexes for Improvement of Anticancer
Activity.
Journal of Medicinal Chemistry 2009, 52, (4), 916-925.
A.1 Introduction
Ruthenium(II) arene complexes represent a new class of anticancer compounds that have
shown cytotoxicity

in cells displaying cisplatin-resistance.1-3 In fact, two Ru(III)

compounds have made it into clinical evaluations.4-6 Ruthenium compounds have
attracted considerable attention due to the fact their tumor-inhibiting effects are different
from platinum compounds.7, 8 However, similar to cisplatin anticancer complexes, Ru(II)
complexes show a preferred binding target at the guanine N7 site of DNA.1,

9, 10

As

mentioned in Chapter 1, the toxicity, side effects, and developed resistance has led to the
development of platinum compounds with multiple metal centers,
polynuclear platinum compounds described therein.

such as the

Polynuclear Ru compounds are

relatively new and therefore have rarely been studied for their anticancer properties.6, 11, 12
The few studies performed on their anticancer activity showed a level of cyctoxicity
lower than that of a mononuclear ruthenium compound.

6, 11, 12

This is remarkably

different in the case of platinum compounds, where the introduction of polynuclear
platinum centers actually increases the cytoxicity and leads to overcoming cisplatin
resistance.13
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Figure A.1 Structure of Dinuclear Ru(II)-arene complex with (n) = alkyl
chain length
Expanding on the recent success of multinuclear platinum complexes, like the clinically
relevant BBR 3464, a multicentered Ru(II)

compound was synthesized by our

collaborators see Figure A.1.6, 14 The concept behind these compounds was to have alkyl
chains of varying lengths. The most potent of these compounds in A2780 cell lines was
when the alkyl spacer was n=6.7 As such, the n=6 alkyl chain spaced compound was
chosen to study its binding to DNA.

A.2 Experimental
For the MS studies, the non-self complementary DNA 13-mer 5’-ATC TGT TTG TCT T3’ (3921 Da; Midland Certified Reagents, Midland TX) was incubated with Ru(II) in
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H2O at DNA : complex ratios ranging from 5 : 1 (rB 0.015) to 1 : 5 (rB 1.5). Before use,
the purified 13-mer was further desalted using a custom built dialysis chamber equipped
with a hollow micro dialysis fiber with a 13 000 molecular weight cut off (MWCO) from
Spectrum Laboratories (Rancho Dominguez, CA) in 25 mM ammonium acetate solution.
The desalted oligonucleotide was lyophilized to dryness and reconstituted in 18 MΩ
water.
The sample mixtures were analyzed immediately after mixing and after 30 min and 24 h
of incubation on a Waters/Micromass Qtof-2 (Manchester, UK) instrument equipped with
a custom built micro-spray source operated in negative ion mode over a mass range of
500–2000 m/z. Samples were introduced into the inlet at 1.0 µL/min with a capillary
voltage of –1.9 kV and a cone voltage of 36 V. The source temperature was maintained
constant at 110 ºC throughout the experiments. A 1: 1 mixture of methanol : water (with
25 mM ammonium acetate) was used as the spray solvent. Data were collected and
processed using the Mass Lynx 4.0 software and the deconvolution to molecular mass
scale was performed using the maximum entropy (Max Ent) software supplied with the
instrument.

A.3 Results and Discussion

In efforts to determine the affinity of the dinuclear Ru(II) compound in Figure A1., the
binding with a 13-mer single stranded oligonucleotide was undertaken. Different
DNA : complex ratios were prepared and the amount of bound ruthenium increased with
the rB. For example, at rB = 0.15 the 13-mer and an adduct assignable to 13-mer +
[Ru(II) – 2Cl] (4721 Da) were observed at a relative intensity of ca. 1:1.When increasing
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the rB = 0.46, there is a significant decrease in the free oligonucletide resulting in
approximately 40% free oligonucleotide. Incubation of the complexes at an rB = 1.0,
results in the formation of a bisadduct, attained (13-mer + [2 Ru(II) – 4 Cl], 5521 Da),
and at rB = 1.5 the ratio between these two adducts was found to be 1 : 1 with no
unruthenated 13-mer being detectable. The reactivity of Ru(II) for the available binding
sits of nucleobases follows the order: G(N7) > T(N3) > C(N3) > A(N7), A(N1).15 Given
the number of thymine nucleobases present in the sequence, it is plausible for the single
strand to contain multiple covalently bonded Ru(II) compounds. It is not possible to
further increase the concentration of Ru(II) since this induces the precipitation of the 13mer. Furthermore, precipitation was observed in all samples with rB > 1 and when
incubating the mixtures for 24 hr. It should be noted that free 13-mer ion intensity was
much lower at the higher rB values and in overnight incubations. The covalent binding
under these conditions is extremely rapid and no significant changes were scene at
incubation times of longer than 1hr. Given the presence of two available guanines in the
13-mer sequence, it was also considered that the dinuclear complex could cross-link two
13-mer single strands: however, such species were not observed in the mass spectra but
their presence cannot be excluded from the precipitate found after longer incubation
times and higher rB values. The complexation of Ru(II) dinuclear complexes with single
stranded DNA displayed rapid covalent binding event with no detectable aquo species
present.
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Figure A.2. Deconvoluted ESI-MS of 13-mer single strand DNA with Ru(II)
compound at varying rB values. (1) free 13-mer, (2) 1:1 mixture, rB = 0.15 (3) 1:3
mixture, rB = 0.46 (4) 1:7 mixture, rB = 1.07 (A) free 13-mer, (B) 1:1 Ru:Oligo,
(C)2:1 Ru:Oligo
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A.4 Conclusions

The influence of coupling two Ru(II) moieties together via an alkyl chain was
investigated with regard to binding ratios on a single stranded 13-mer oligonucleotide
sequence. As DNA is the ultimate target for platinum anticancer agents, the results
described show that dinucler Ru(II) complexes also exhibit a strong interaction with
nucleotides.

Rapid and favorable complexation between the Ru(II) compound and

oligonucleotide was identified.

The amount of “ruthenation” increased with the rB

values. While higher rB values could have been investigated, the level of precipitation in
the solution led to inconclusive results when electrosprayed.

A more detailed

examination of the binding mechanism is needed and expansion into duplex
oligonucletides is also warranted.
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Appendix B.
Interaction of Covalent Polynuclear Compounds with a Zinc Finger Model

B.1. Introduction
The nucleocapsid NCp7 protein represents a very attractive target for antiviral drug compounds.1
Nucleocapsid proteins characteristically contain a conserved region of CCHC sequence, Cys-X2Cys- X4-His- Cys (X= variable sequence).2,

3

The NCp7 nucleocapsid protein for human

immunodeficiency virus type 1 (HIV-1) has two highly conserved zinc finger domains necessary
for successful viral replication,3-5 NCp7 have a high affinity for single stranded nucleic acids 3, 6,
7

, has been shown to act as a chaperone nucleic acid folding/unfolding events and are generally

involved in numerous events in the viral replication.8
Efforts to disrupt the function of the NCp7 proteins have involved covalent modification of the
protein through the use of strong electrophiles that modify the zinc binding site.9 The end result
of this modification is the cleavage of the Zn-S bond and eventual zinc ion release resulting in
inactivity via the loss of the important tertiary structure.3 Our group has successfully modified
zinc finger models with mononuclear platinum compounds (trans-[PtCl(9-EtGH)(py)2]2+),
resulting in covalent modification, zinc ejection, and changes in protein conformation.3, 10
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B.2. Experimental
Dinuclear platinum compounds were synthesized in house as previously described.11,

12

The

peptide (KGCWKCGKQEHQMKDCTER) was purchased from GeneScript and used as purified.
To prepare the zinc finger, the previously described protocol was followed.10 Briefly, zinc
acetate and the peptide were dissolved in an ~ 1.2:1.0 equimolar ratio in water with the final pH
adjusted to 7.0 using ammonium hydroxide. The zinc finger peptide was incubated
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Figure B.1 Structures of the dinuclear platinum compounds 1,1/cc
(upper) and 1,1/tt (lower)

for 2 hrs at 37 °C. Formation of the zinc finger peptide was confirmed with ESI-MS and circular
dichroism. The sample mixtures were analyzed on a Waters/Micromass Qtof-2 (Manchester,
UK) instrument equipped with a custom built micro-spray source operated in positive ion mode
over a mass range of 200–2000 m/z. Samples were introduced into the inlet at 1.0 µL/min with a
capillary voltage of 1.8 kV and a cone voltage of 30 V. The source temperature was maintained
constant at 120 ºC throughout the experiments. Collision gas was introduced into the hexapole to
aid in ion cooling. Data were collected and processed using the Mass Lynx 4.0 software.
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B.3. Results and Discussion
The reaction of dinuclear platinum compounds can be monitored by ESI-MS to give an
approximate identification of the species formed over time. Figure B.2. shows the ESI-MS
spectra of the reaction between 1,1/cc and ZF at a 1:1 ratio at T= 0 and T= 4hrs. Figure B.2.A
corresponds to the 2+ free zinc finger at 1144 m/z and B.2.B represents the 3+ zinc finger-Pt
complex (922 m/z) in which the 1,1/cc is bound covalently with a bidentate coordination on both
platinum centers. Additionally, this type of binding structure results in the loss of the essential
zinc ion.

Incubation of the solution at longer time periods reveals an increase in the 922 m/z

ion. Under these reaction conditions, there does not appear to be any appreciable monodentate
binding of the platinum centers as would be expected.
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Figure B.2. ESI-MS of 1,1/cc with intact zinc finger at t = 0 and t = 4hrs.
(A) in both plots is free intact zinc finger and (B) is a bidentate
coordination of 1,1/cc with subsequent zinc ejection
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Figure B.3. ESI-MS of 1,1/tt with intact zinc finger at t = 0 and t = 4hrs. (A) in
both plots is free intact zinc finger and (B) is a bidentate coordination of 1,1/tt with
a cleavage of the –KG- amino acids from the intact peptide.

Switching to the 1,1/tt trans dinuclear compound reveals a slightly more reactive interaction in
the fact that multiple ion peaks are present throughout the spectra. Figure B.3.A again shows the
free 2+ zinc finger peptide at 1144 m/z. At the first initial time point t = 0, there does not appear
to be any interaction between the two species. However, after 4 hrs of incubation, a substantial
peak appears at 894 m/z corresponding to the 3+ charge state of the peptide/Pt interaction.
However, upon closer inspection, the mass of an intact 1,1,/tt complex with the peptide would
result in a higher mass to charge ratio. The corresponding mass of the 3+ ions reveals that a
cleavage of the KG- amino acids from the intact peptide may have occurred.

Platinum

compounds have been shown to induce a hydrolytic cleavage of peptides, but generally at very
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low pH, ~2. This reaction was down initially at pH= 7.0, but may have lowered due to the
reaction.
While structural assignments are difficult to determine, an ms/ms of the 894 m/z peak Figure
B.4., reveals fragmentation products relating to the y1, y2, y3, y4, y8, and y132+. This would give a
remaining peptide sequence of -CWKC- which is a probable binding site due to the thiols of the
cysteine residues. The dominant fragment ions in the ms/ms spectra are those of the y-type ions.
As such, no discernible fragment ions are identified for the N-terminus ions with or without
platinum adducts.
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B.4. ESI-MS/MS of the 3+ 894m/z peak. Fragmentation products yield
primarily y-type ions. The region of CWKC is absent from the spectra and
may indicate the binding site of the 1,1/tt.
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Under gentle conditions it was also noticed that an electrostatic association occurred during the
early time points. The association of intact 1,1/tt with the zinc finger was identified as a 3+ peak
at 978 m/z. This peak was confirmed to be an electrostatic association by performing ms/ms at
increasing collisional energies.

Figure B.5 shows the resultant ms/ms of the electrostatic

association at peak 978 m/z. Peak A produced from the ms/ms represents the intact zinc finger at
1144 m/z and the peak labeled B represents the intact 1,1/tt compound at 644m/z. Also,
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B.5 ESI-MS/MS of the electrostatic association of 1,1/tt or 1,1/cc with the
intact zinc finger m/z = 978. (A) is the free intact zinc finger. (B) is the
intact dinuclear platinum compound. Additional peaks left of (B) are the
subsequent loss of the chloro ligands from the platinum moiety.
identifiable are the peaks corresponding to the sequential loss of the two Cl- produced during the
collision event, at 609 and 574 m/z respectively.
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B.4. Conclusions
The reaction of dinuclear platinum compounds with a model zinc finger peptide reveal subtle
differences in the cis and trans geometries. While a reaction scheme cannot be ascertained at the
present time, what can be determined is that the cis geometry provides the most stable (in terms
of few species) complex. The downside of the trans geometry is the reaction with sulfur groups
often results in the trans effect breakdown of the compound. Not shown in the presented spectra,
but evident throughout the 1,1/tt experiments, were the platinum fragments commonly associated
with trans effect.
The reaction of these covalent dinuclear platinum compounds with zinc finger models is difficult
to characterize due to the abundance of species present. Further work is necessary to accurately
determine the species present in solution. Nevertheless, covalent modification of zinc finger
complexes with platinum moieties results in loss of zinc ions and therefore may eventually find a
niche in treatment as an antiviral therapeutic.
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